Track market-moving stories before they get noisy

Novanta Inc. (NOVT) Q1 2026 Earnings Call Transcript

-

BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, is scheduled to present at Jefferies Global Healthcare Conference on Thursday, June 4, 2026, in New York, NY.

About Novanta

Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary technology expertise and competencies in precision medicine and manufacturing, medical solutions, and robotics and automation with a proven ability to solve complex technical challenges. This enables Novanta to engineer core components and sub-systems that deliver extreme precision and performance, tailored to our customers' demanding applications. The driving force behind our growth is the team of innovative professionals who share a commitment to innovation and customer success. Novanta’s common shares are quoted on Nasdaq under the ticker symbol “NOVT.”

More information about Novanta is available on the Company’s website at www.novanta.com. For additional information, please contact Novanta Inc. Investor Relations at (781) 266-5137 or [email protected].

More News From Novanta Inc.

Back to Newsroom

On May 20, 2026, Novanta Inc NOVT shares rose 4.0% today, bringing the current price to $153.60. The stock has experienced a 52-week range of $98.27 to $165.56, reflecting significant volatility and investor interest over the past year.

GF Value™ verdict: Current price is $153.60, which is 0.4% below the GF Value™ of $154.26.GF Score™: 89/100, indicating a strong overall rating based on key financial metrics.Most notable signal: Insider activity shows that insiders sold $5.1M in the last 3 months, with no purchases reported. Is NOVT Overvalued or Undervalued? Currently, Novanta Inc's shares are trading at $153.60, which represents a slight discount of 0.4% relative to the GF Value™ of $154.26. This minor margin of safety suggests that the stock is fairly valued according to the GF Value™ methodology, which estimates intrinsic value based on historical trading multiples, past business growth, and future performance estimates. Given the relatively close alignment between the stock price and the GF Value™, there appears to be minimal risk of significant overvaluation at this time.

However, while the stock is deemed fairly valued, potential investors should be cautious of the recent insider selling activity, which might signal a lack of confidence from those closest to the company. This factor, along with the strong GF Score™ of 89/100, indicates that while there is no immediate opportunity in terms of undervaluation, the company still possesses robust fundamentals worthy of consideration.

How Does NOVT's Valuation Compare to Its History? MetricCurrentHistorical P/E (TTM)111.3x81.3x Forward P/E42.8xN/A The current P/E ratio of 111.3x is significantly above its 5-year median P/E of 81.3x, indicating that the stock is trading at a premium compared to its historical valuation. This analysis supports the GF Value™ verdict, suggesting that while the stock is currently fairly valued, it is also trading at a higher multiple than its historical average, which could imply a risk of overvaluation in the future.

What Does NOVT's GF Score™ Tell Us? MetricRating GF Score™89/100 Financial Strength8/10 Profitability9/10 Growth6/10 Valuation9/10 Momentum8/10 Novanta's GF Score™ of 89/100 reflects a strong performance across several key aspects of the business. The highest ratings are in Profitability (9/10) and Valuation (9/10), indicating that the company not only generates solid profits but is also perceived as having a fair valuation based on its performance metrics. The weakest area is Growth (6/10), suggesting that while the company is doing well, its growth potential may not be as robust as some of its peers. Overall, these scores position Novanta as a strong candidate for long-term stability.

What Are Insiders Doing with NOVT Stock? Recent insider activity for Novanta Inc indicates that insiders have sold $5.1 million worth of stock over the past three months, with no reported insider purchases. This pattern of selling could imply a lack of confidence among insiders regarding the stock's near-term prospects, which might be a point of concern for potential investors. While insider selling does not always predict declines, it can be a signal to watch closely.

What This Means for Investors Based on the analysis, Novanta Inc NOVT is currently fairly valued according to GF Value™, with a slight margin of safety. Investors should remain vigilant regarding the insider selling activity and consider the implications of the current high P/E ratio relative to historical valuations. Overall, the strong GF Score™ suggests a solid foundation, but caution is advised given recent insider movements.

For the complete analysis, visit the Novanta Inc NOVT stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is NOVT's GF Score™?

The GF Score™ for Novanta Inc is 89/100, indicating a strong overall rating based on financial strength, profitability, growth, valuation, and momentum.

Is NOVT overvalued or undervalued?

Novanta Inc is currently fairly valued according to GF Value™, with a current price of $153.60 that is 0.4% below the estimated fair value of $154.26.

What is NOVT's P/E ratio?

Novanta Inc's P/E ratio is 111.3x, which is significantly above its 5-year median P/E of 81.3x, indicating that the stock is trading at a premium compared to its historical valuation.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

On June 08, 2026, Novanta Inc NOVT shares rose 5.1% to $164.34. This increase comes amid a strong year-to-date performance, with shares up 38.1%, and a significant rise of 18.8% over the past month. The stock has seen a 52-week range between $98.27 and $171.85.

GF Value™ verdict: Current price is $164.34, which is 6.8% above the GF Value™ estimate of $153.89.GF Score™: 87/100, indicating a strong overall rating.Most notable signal: Insider activity shows that insiders sold $5.1M worth of shares in the last three months, with no buying reported. Is NOVT Overvalued or Undervalued? According to the GF Value™, Novanta Inc is currently overvalued by 6.8%, with a current price of $164.34 exceeding its fair value estimate of $153.89. This implies that the stock is trading above its intrinsic value, suggesting a lack of a margin of safety for potential investors. The GF Valuation label indicates that the stock is fairly valued, which aligns with the conclusion drawn from the GF Value™ analysis. However, being overvalued poses risks, as a correction may occur if market sentiment shifts or if the company's performance fails to meet expectations.

GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.

How Does NOVT's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 119.1x 81.3x Forward P/E 45.8x N/A Novanta's current P/E (TTM) of 119.1x is significantly higher than its 5-year median P/E of 81.3x, indicating that the stock is trading above its historical valuation levels. The forward P/E of 45.8x suggests some anticipated earnings growth, but the stark difference between the current and historical P/E ratios supports the GF Value™ verdict that the stock is overvalued.

What Does NOVT's GF Score™ Tell Us? Metric Rating GF Score™ 87 Financial Strength 8/10 Profitability 9/10 Growth 6/10 Valuation 7/10 Momentum 8/10 The GF Score™ of 87/100 highlights Novanta's strong position, particularly in profitability with a score of 9/10 and financial strength with 8/10. However, its growth rank of 6/10 indicates that there may be room for improvement in this area. Overall, the scores suggest that while Novanta is performing well in terms of profitability and financial stability, its growth potential may not be as robust as other factors would indicate.

What Are Insiders Doing with NOVT Stock? Recent insider activity shows that insiders have sold $5.1 million worth of shares in the last three months, without any buying activity reported. This trend may suggest a lack of confidence from insiders regarding the stock's future performance, which can be a cautionary signal for potential investors. Such selling might indicate that insiders believe the current price is at a peak or that they are taking profits.

What This Means for Investors Based on the GF Value™ analysis, Novanta Inc is currently overvalued at $164.34 compared to its estimated fair value of $153.89. This overvaluation, combined with recent insider selling activity, suggests potential risks for investors considering an entry point at this price.

For the complete analysis, visit the Novanta Inc NOVT stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is NOVT's GF Score™?

NOVT's GF Score™ is 87/100, indicating a strong overall performance based on key metrics. Stocks with higher GF Score™ values are associated with better long-term returns.

Is NOVT overvalued or undervalued?

NOVT is currently overvalued, with a GF Value™ of $153.89 compared to its market price of $164.34, indicating potential risks for investors.

What is NOVT's P/E ratio?

NOVT's P/E (TTM) is 119.1x, significantly higher than its 5-year median P/E of 81.3x, suggesting that the stock is trading above its historical valuation levels.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

-

BOSTON--(BUSINESS WIRE)--Novanta Inc. ("Novanta" or the “Company”) announced today that it has entered into a securities purchase agreement for a private placement of the Company’s common shares (“Common Shares”) to institutional and other accredited investors that is expected to result in gross proceeds of approximately $300 million to the Company, before placement agent fees and offering expenses.

Pursuant to the terms of the securities purchase agreement, the investors agreed to purchase an aggregate of 2,142,857 Common Shares at a purchase price of $140.00 per share. The private placement is expected to close on or about June 11, 2026, subject to satisfaction of customary closing conditions.

The offer and sale of the foregoing Common Shares are being made in a transaction not involving a public offering and the Common Shares have not been registered under the Securities Act of 1933, as amended, and may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements. Concurrently with the execution of the securities purchase agreement, the Company and the investors also entered into a registration rights agreement pursuant to which the Company has agreed to register the resale of the Common Shares sold in the private placement.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to various risks and uncertainties and include all statements that are not historical statements of fact and those regarding Novanta's intent, belief or expectations. Forward-looking statements are generally identifiable by use of forward-looking terminology such as "may," "will," "could," "potential," "intend," "expect," "estimate," "believe," "plan," or other similar words or expressions, and include statements regarding the closing of the private placement, Novanta’s agreement to register the resale of the securities issued in the private placement and the expected amount of proceeds from the private placement. Although Novanta believes that expectations reflected in any forward-looking statements are based on reasonable assumptions, it can give no assurance that its assumptions or expectations will be attained, and actual results and performance could differ materially from those projected. Factors which could have a material adverse effect on Novanta's operations and future prospects or which could cause events or circumstances to differ from the forward-looking statements include, but are not limited to the risks detailed from time to time in Novanta's filings with the SEC, including those set forth in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. When considering forward-looking statements, you should keep in mind the risk factors and other cautionary statements in such SEC filings. Readers are cautioned not to place undue reliance on any of these forward-looking statements, which reflect management's views as of the date of this press release. Novanta cannot guarantee future results, levels of activity, performance or achievements, and, except as required by law, it expressly disclaims any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations with regard thereto or change in events, conditions or circumstances on which any statement is based.

More News From Novanta Inc.

Back to Newsroom

, /PRNewswire/ -- Dana Incorporated (NYSE: DAN) will release its 2026 first-quarter financial results on Wednesday, Apr. 29, 2026. A press release will be issued at approximately 7 a.m. EDT, followed by a conference call and webcast at 9 a.m. EDT. Members of the company's senior management team will be available at that time to discuss the results and answer related questions.

The conference call can be accessed by telephone from both domestic and international locations using the information provided below:

Conference ID: 9943139
Participant Toll-Free Dial-In Number: (800) 715-9871
Participant Toll Dial-In Number: +1 (646) 307-1963

Audio streaming and slides will be available online via a link provided on the Dana investor website: www.dana.com/investors. 

A webcast replay can be accessed via Dana's investor website following the call.

About Dana Incorporated
Dana Incorporated (NYSE: DAN) is a global leader in the design and manufacture of highly efficient propulsion solutions for the light- and commercial‑vehicle markets. Guided by its vision to be the world's best powertrain company, Dana delivers advanced conventional and clean‑energy technologies that help customers improve the performance, efficiency, and durability of their vehicles. The company supplies leading vehicle manufacturers and related aftermarkets with industry‑defining drive systems, electrodynamic technologies, and thermal and sealing solutions.

Headquartered in Maumee, Ohio, USA, Dana reported sales of $7.5 billion in 2025. With a history dating to 1904, the company employs 27,000 people in 24 countries across six continents. Learn more at dana.com.

SOURCE Dana Incorporated

-

Peer-reviewed study finds standard HER2 IHC testing shows limited predictive value for T-DXd while Ignite’s platform — the only commercially available multiplex assay in the study—demonstrates predictive value for patient outcomes

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced that its precision oncology subsidiary, Ignite Proteomics, LLC (“Ignite” or “Ignite Proteomics”), has been featured in a peer-reviewed study published online ahead of print in npj Precision Oncology, a Nature journal. The study, led by investigators at Dana-Farber Cancer Institute, evaluated outcomes among patients with metastatic breast cancer treated with trastuzumab deruxtecan (T-DXd, marketed as Enhertu® by AstraZeneca and Daiichi Sankyo) and assessed multiple quantitative HER2-related assays for their association with treatment outcomes.

While conventional HER2 immunohistochemistry (IHC) showed some association with outcomes in the broader patient population, the study found that quantitative HER2-related assays provided more granular predictive information in several matched biomarker sub-cohorts. In those sub-cohorts, traditional IHC classification often showed limited predictive value compared with quantitative approaches. Ignite’s Reverse Phase Protein Array (RPPA) platform, the only commercially available multiplex assay in the study, was one of the quantitative methods that demonstrated meaningful predictive value for patient outcomes.

T-DXd is an approved treatment option for a broad population of patients with metastatic breast cancer, yet there is currently no reliable way to predict which patients will respond.

“According to several studies, approximately 40% of cancers do not respond to the FDA approved therapy at front line in a metastatic setting,” said Jeff Busch, Chief Executive Officer of Ignite Proteomics. In oncology, published research and institutional analyses have shown that approved therapies often fail to benefit a substantial portion of the patients who receive them. A 2017 study published in the BMJ reported that 57% of cancer drug indications approved by the European Medicines Agency entered the market without evidence of improved survival or quality-of-life benefit. MIT researchers have noted that targeted tyrosine kinase inhibitors typically work for only 40% to 80% of patients expected to respond. Johns Hopkins has reported that only 15% to 20% of patients achieve durable results with immunotherapy.

Ignite’s RPPA platform measures multiple protein biomarkers, including pathway activation and payload-relevant markers, from a single tumor sample. In the Dana-Farber study, Ignite’s platform was the only commercially available multiplex assay evaluated and demonstrated predictive value in matched biomarker cohorts where conventional HER2 IHC showed limitations. Notably, the study found that TOPO1 expression, the target of T-DXd’s cytotoxic payload, was detectable by Ignite’s platform in certain HER2-negative patients, highlighting the potential value of measuring tumor biology beyond HER2 expression alone. Ignite’s assay is CLIA-certified, CAP-accredited, listed on the Medicare Clinical Laboratory Fee Schedule under AMA CPT code PLA 0249U, and orderable today on standard biopsy tissue.

“Cancer therapy has made extraordinary progress, but oncology still has a treatment-selection problem,” added Busch. “Too many patients receive therapies without enough information about whether those therapies are likely to work for their tumor biology. That is not an indictment of the drugs. These are powerful therapies. The issue is that cancer is complex, and single-marker testing often does not capture the functional biology that drives response or resistance. Ignite’s RPPA platform was built to address that gap by measuring multiple proteins, pathway activation, and payload-relevant biology from the same tumor sample. In this study, one of the world’s leading breast cancer research teams evaluated our platform alongside standard testing, and our platform demonstrated predictive value where conventional testing had limitations. That is the opportunity: better data, better treatment selection, and fewer patients receiving therapies that were never likely to help them.”

“This publication represents an important milestone for our subsidiary Ignite and reflects the strength of Aditxt’s model of advancing and scaling impactful health innovations,” said Amro Albanna, Co-Founder and Chief Executive Officer of Aditxt. “Peer-reviewed clinical evidence from one of the world’s leading cancer research institutions is key to accelerating the commercialization of this platform and expanding access to it for millions of patients making treatment decisions without clear guidance on what will work. Our goal is to help ensure that more patients receive the right therapy at the right time, with the potential to improve outcomes and make a meaningful difference in people’s lives.”

The full study is available open access at: https://doi.org/10.1038/s41698-026-01365-6

About Ignite Proteomics, LLC

Ignite Proteomics delivers pathway‑level protein analytics to guide precision oncology. Operating a CLIA‑certified, CAP‑accredited laboratory, Ignite's clinical RPPA assay quantifies 32 phospho- and total-protein biomarkers from limited biopsy material to support oncology research and clinical decision making.

About Aditxt, Inc.

Aditxt, Inc. is a social innovation platform accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives its mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress. The Company currently operates four programs focused on autoimmunity, cancer and early disease detection, infectious diseases and women’s health.

Forward-Looking Statements

This press release includes "forward-looking statements," within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "aim," "believe," "could," "expect," "intend," "may," "plan," "potential," "seek," "will," and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the significance of the published study, Ignite’s commercialization plans, the potential clinical utility of its platform, expected collaborations, publications, reimbursement, adoption, and international expansion. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in each company’s SEC filings, including Aditxt’s Annual Report on Form 10-K and any subsequent Form 10-Q filings, including the most recent filed on November 18, 2025. All forward-looking statements are expressly qualified in their entirety by such factors. Aditxt undertakes no duty to update any forward-looking statement except as required by law.

More News From Aditxt, Inc.

Back to Newsroom

First- Quarter Highlights:

Sales of $1.9 billion and increase of five percent over the first quarter of 2025 Adjusted EBITDA of $171 million; $78 million higher than first quarter of 2025 9.2 percent adjusted EBITDA margin; 400 basis points higher than prior year Completed sale of the Off‑Highway business Achieved $35 million in additional cost savings Repurchased 4.4 million shares, returning $125 million to shareholders Announced significant new business win , /PRNewswire/ -- Dana Incorporated today announced its first‑quarter 2026 financial results, delivering strong performance and maintaining full-year guidance. 

"Dana's long-term strategy is clear and built on actions fully within our control – improving our cost structure and executing with discipline" said R. Bruce McDonald, Chairman and Chief Executive Officer.  "Our first-quarter results demonstrate our progress with meaningful margin expansion and continued momentum in new business wins. The Dana 2030 plan outlines a clear path to higher sales, structurally higher margins and increased adjusted free cash flow generation. With a best in sector balance sheet, we have continued to generate meaningful value to our shareholders through a continued commitment to disciplined capital allocation."

Sales in the first quarter of 2026 totaled $1.87 billion, compared with $1.78 billion in the same period of 2025. The improvement was driven by customer recoveries and currency translation.

Adjusted EBITDA for the first quarter was $171 million representing a 9.2 percent margin, compared with $93 million, or 5.2 percent, for the same period in 2025. Cost-savings actions and efficiency improvements were the primary drivers of the improvement.

Operating cash flow in the first quarter of 2026 was a use of $156 million, compared with a use of $37 million in the same period of 2025. Adjusted free cash flow was a use of $195 million, compared with a use of $101 million in the first quarter of 2025. 

Dana announced a new business award with Stellantis for the RAM Dakota program, expanding the company's presence in the compact truck market. The award includes the supply of front drive units and rear axles for an all‑new vehicle platform, with production expected to begin in early 2028. This win increases Dana's three‑year net new sales backlog to approximately $950 million, reinforcing continued momentum in high‑quality new business.

"Dana 2030 establishes ambitious long‑term targets, and our near‑term focus is on translating that vision into sustained execution and performance improvement," said Byron Foster, incoming Chief Executive Officer of Dana Incorporated. "The pace of recent new business wins demonstrates the strength of our product portfolio and reinforces Dana's long‑term growth trajectory. As macro and market conditions begin to improve, we are unlocking incremental operating leverage. At the same time our teams are executing with discipline, improving efficiency, and positioning Dana to deliver increased performance throughout the year."

2026 Financial Targets

Revised Guidance

Sales

$7.30 to $7.70 billion

Adjusted EBITDA

$750 to $850 million

Implied adjusted EBITDA margin

10.0% to 11.0%

Diluted Adjusted EPS

$2.00 to $3.00

Adjusted free cash flow

$250 to $350 million

Dana to Host Conference Call at 9 a.m. Wednesday, April 29
Dana will discuss its first quarter 2026 results in a conference call at 9 a.m. EDT on Wednesday, April 29. The conference call can be accessed by telephone from both domestic and international locations using the information provided below:

Conference ID: 9943139
Participant Toll-Free Dial-In Number: (800) 715-9871
Participant Toll Dial-In Number: 1 (646) 307-1963

Audio streaming and slides will be available online via a link provided on the Dana investor website: www.dana.com/investors. Phone registration will be available beginning at 8:30 a.m. EDT.

A webcast replay can be accessed via Dana's investor website following the call.

Non-GAAP Financial Information
Adjusted EBITDA is a non-GAAP financial measure which we have defined as net income (loss) before interest, income taxes, depreciation, amortization, equity grant expense, restructuring expense, non-service cost components of pension and other postretirement benefit costs and other adjustments not related to our core operations (gain/loss on debt extinguishment, pension settlements, divestitures, impairment, etc.). Adjusted EBITDA is a measure of our ability to maintain and continue to invest in our operations and provide shareholder returns. We use adjusted EBITDA in assessing the effectiveness of our business strategies, evaluating and pricing potential acquisitions and as a factor in making incentive compensation decisions. In addition to its use by management, we also believe adjusted EBITDA is a measure widely used by securities analysts, investors and others to evaluate financial performance of our company relative to other Tier 1 automotive suppliers. Adjusted EBITDA should not be considered a substitute for earnings (loss) before income taxes, net income (loss) or other results reported in accordance with GAAP. Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies.

Adjusted free cash flow is a non-GAAP financial measure which we have defined as net cash provided by (used in) operating activities less purchases of property, plant and equipment plus proceeds from sale of property, plant and equipment plus cash paid for purchases of leased facilities plus cash paid for Off-Highway business divestiture related costs.  We believe adjusted free cash flow is useful to investors in evaluating the operational cash flow of the company inclusive of the spending required to maintain the operations.  Adjusted free cash flow is not intended to represent nor be an alternative to the measure of net cash provided by (used in) operating activities reported in accordance with GAAP.  Adjusted free cash flow may not be comparable to similarly titled measures reported by other companies.

Reconciliations of adjusted EBITDA and adjusted free cash flow to the most directly comparable financial measures calculated and presented in accordance with GAAP will be included in our quarterly report on Form 10-Q for the three months ended March 31, 2026. We have not provided a reconciliation of our adjusted EBITDA outlook to the most comparable GAAP measures of net income (loss). Providing net income (loss) guidance is potentially misleading and not practical given the difficulty of projecting event driven transactional and other non-core operating items that are included in net income (loss), including restructuring actions, asset impairments and certain income tax adjustments. The reconciliations of these non-GAAP measures with the most comparable GAAP measures for the historical periods presented are indicative of the reconciliations that will be prepared upon completion of the periods covered by the non-GAAP guidance.

Forward-Looking Statements
Certain statements and projections contained in this news release are, by their nature, forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements are based on our current expectations, estimates, and projections about our industry and business, management's beliefs, and certain assumptions made by us, all of which are subject to change.  Forward-looking statements can often be identified by words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "could," "potential," "continue," "ongoing," and similar expressions, and variations or negatives of these words.  These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties, and assumptions that could cause our actual results to differ materially and adversely from those expressed in any forward-looking statement. 

Dana's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, recent Current Reports on Form 8-K, and other Securities and Exchange Commission filings discuss important risk factors that could affect our business, results of operations and financial condition.  The forward-looking statements in this news release speak only as of this date. Dana does not undertake any obligation to revise or update publicly any forward-looking statement for any reason.

About Dana Incorporated
Dana Incorporated (NYSE: DAN) is a global leader in the design and manufacture of highly efficient propulsion solutions for the light- and commercial‑vehicle markets. Guided by its vision to be the world's best powertrain company, Dana delivers advanced conventional and clean‑energy technologies that help customers improve the performance, efficiency, and durability of their vehicles. The company supplies leading vehicle manufacturers and related aftermarkets with industry‑defining drive systems, electrodynamic technologies, and thermal and sealing solutions.

Headquartered in Maumee, Ohio, USA, Dana reported sales of $7.5 billion in 2025. With a history dating to 1904, the company employs 27,000 people in 24 countries across six continents. Learn more at dana.com

SOURCE Dana Incorporated

SAGUENAY, Quebec, May 14, 2026 (GLOBE NEWSWIRE) -- Arianne Phosphate Inc (the “Company” or “Arianne”) (TSX VENTURE: DAN; OTCQB: DRRSF; FRANKFURT: JE9N), a development-stage phosphate mining company, advancing the Lac à Paul project in Quebec’s Saguenay-Lac-Saint-Jean region, is pleased to announce that phosphoric acid has been successfully produced on a continuous basis using its high-purity phosphate concentrate. This accomplishment marks the first time phosphoric acid has been continuously produced in the Province from a Quebec-sourced apatite concentrate in over 130 years. This work was done in partnership with Corem and with the support of Natural Resources Canada (NRCan).

“The importance of phosphate continues to grow while at the same time supply chains are increasingly threatened by geopolitical events,” said Raphael Gaudreault, COO of Arianne Phosphate. “This breakthrough is yet another example of the quality of our phosphate concentrate and demonstrates the opportunity for a fully localized phosphate supply chain here in Quebec, Canada, that could end a century of dependence on imported rock. Further, much of the world is now questioning its supply chains and this work shows how Arianne will be an important and trusted partner to the West for this critical material. This work strengthens Canada’s critical minerals strategy, secures domestic feedstock and positions Quebec as the North American leader in the green energy transition.”

During tests performed at Corem, the Company produced roughly 1.5 tonnes of phosphoric acid on a continuous basis over a one-week period. Due to the nature of Arianne’s phosphate concentrate, the phosphoric acid produced is easily upgraded to a purified phosphoric acid (see Press Release dated April 9, 2026), the material required for the LFP battery industry as well as high-performance fertilizers, pharmaceuticals and semiconductor production. Additionally, Arianne’s phosphate concentrate requires considerably less sulphuric acid to produce its phosphoric acid, another significant advantage as almost 50% of sulphur flows through the Strait of Hormuz.

“For many years the supply of phosphate was taken for granted with few questioning accesses to this critical material,” said Brian Ostroff, Head of Strategic and Business Initiatives. “Despite these headwinds, Arianne spent $100 million dollars and over 15 years advancing its Lac à Paul project. Today, Arianne owns the world’s largest greenfield phosphate deposit that can produce a very pure phosphate concentrate and, is the West’s only permitted phosphate mine. With government, industry and investors now understanding this challenging macro, the importance of Arianne should be underscored.”

Adoption of semi-annual financial reporting

Additionally, the Company announces adoption of semi-annual financial reporting ("SAR"). This news release is being issued and filed pursuant to Coordinated Blanket Order 51-933 Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers ("CBO 51-933").

CBO 51-933 allows eligible venture issuers to voluntarily move from a quarterly to a semi-annual financial reporting framework. By adopting SAR, Arianne aims to reduce the administrative and financial burden of quarterly reporting. As a result of adopting SAR, the Company will not file interim financial statements and related Management's Discussion and Analysis ("MD&A") for the three-month period ending March 31 and the nine-month period ending September 30 of each applicable fiscal year. Accordingly, the initial interim period for which the Company does not intend to file an interim financial report and related MD&A will be for the three months ended March 31, 2026. Arianne will continue to file audited annual financial statements (due within 120 days of December 31) and six-month interim financial reports and related MD&A (due within 60 days of June 30). The Company remains committed to timely and transparent disclosure and will continue to report all material changes and significant developments as required under National Instrument 51-102 - Continuous Disclosure Obligations.

Clarification Regarding Bonus Warrants Issued under the Credit Facility Extension

Reference is made to Arianne’s press release dated April 1, 2026 announcing the closing on agreement to extend its credit facilities. The Company confirms that the restriction to exercise the 25 million 2026 Warrants (as defined in the press release) if such exercise would result in the Lender (as defined in the press release) holding, on a partially-diluted basis, more than 19.9% of the issued and outstanding common shares of Arianne also applies in the case of a Business Combination Transaction (as defined in the press release) and, as a result, the exercise of the 2026 Bonus Warrants remains subject to the approval of the TSX Venture Exchange (the “Exchange”) and, if required by the Exchange, of the disinterested shareholders of the Company.

About Arianne Phosphate:
Arianne Phosphate (“Arianne Phosphate Inc.”) (www.arianne-inc.com) is developing the Lac à Paul phosphate deposits located approximately 200 km north of the Saguenay/Lac St. Jean area of Quebec, Canada. These deposits will produce a high-quality igneous apatite concentrate grading 39% P2O5 with little or no contaminants (Feasibility Study released in 2013).

Qualified Person
Raphael Gaudreault, eng., Qualified Person by Regulation 43-101, has approved the technical information in this release. Mr. Gaudreault is also the Company’s Chief Operating Officer.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information:

TechnicalInfoRaphael GaudreaultBrian OstroffChief Operating OfficerHead of Strategic & Business InitiativesTel.: 418-590-1318Tel.: [email protected]@arianne-inc.com   Follow Arianne on:
Facebook: https://www.facebook.com/ariannephosphate
Twitter: http://twitter.com/arianne_dan
YouTube: http://www.youtube.com/user/ArianneResources
Flickr: http://www.flickr.com/photos/arianneresources
Resource Investing News: http://resourceinvestingnews.com/?s=Arianne

Cautionary Statements Regarding Forward Looking Information

This news release contains “forward-looking statements” and “forward-looking information” within the meaning of applicable securities regulations in Canada and the United States (collectively, “forward-looking information”). Forward-looking information includes, but is not limited to, the Company’s anticipated quality and production of the apatite concentrate at the Lac à Paul project. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects, “is expected”, “budget”, “scheduled”, “estimates”, forecasts”, “intends”, “anticipates”, or “believes”, or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, or “will” be taken, occur or be achieved.

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information, including but not limited to: unforeseen delays in the execution of the definitive agreements in connection with the credit facility extension or in obtaining regulatory approval; inability to complete the credit facilities extension by the Closing Date; volatile stock price; risks related to changes in commodity prices; sources and cost of power facilities; the estimation of initial and sustaining capital requirements; the estimation of labour and operating costs; the general global markets and economic conditions; the risk associated with exploration, development and operations of mineral deposits; the estimation of mineral reserves and resources; the risks associated with uninsurable risks arising during the course of exploration, development and production; risks associated with currency fluctuations; environmental risks; competition faced in securing experienced personnel; access to adequate infrastructure to support mining, processing, development and exploration activities; the risks associated with changes in the mining regulatory regime governing the Company; completion of the environmental assessment process; risks related to regulatory and permitting delays; risks related to potential conflicts of interest; the reliance on key personnel; financing, capitalization and liquidity risks including the risk that the financing necessary to fund continued exploration and development activities at Lac à Paul project may not be available on satisfactory terms, or at all; the risk of potential dilution through the issue of common shares; the risk of litigation.

Forward-looking information is based on assumptions management believes to be reasonable at the time such statements are made, including but not limited to, the material terms of the credit facility extension having been agreed to by the parties, continued exploration activities, no material adverse change in commodity prices, exploration and development plans proceeding in accordance with plans and such plans achieving their stated expected outcomes, receipt of required regulatory approval, and such other assumptions and factors as set out herein. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in the forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such forward-looking information. Accordingly, readers should not place undue reliance on forward-looking information. Forward-looking information is made as of the date of this press release, and the Company does not undertake to update such forward-looking information except in accordance with applicable securities laws.

Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Dana Incorporated (NYSE: DAN) announced today it will participate in the UBS Auto and Auto Tech Conference on June 3.  Beginning at 1:00 p.m. EDT, Dana's Incoming Chief Executive Officer Byron Foster and Chairman R. Bruce McDonald and will host a fireside chat for approximately 40 minutes.

Information on accessing the webcast will be posted to Dana's Investor website, www.dana.com/investors, before the event.

About Dana Incorporated
Dana Incorporated (NYSE: DAN) is a global leader in the design and manufacture of highly efficient propulsion solutions for the light- and commercial‑vehicle markets. Guided by its vision to be the world's best powertrain company, Dana delivers advanced conventional and clean‑energy technologies that help customers improve the performance, efficiency, and durability of their vehicles. The company supplies leading vehicle manufacturers and related aftermarkets with industry‑defining drive systems, electrodynamic technologies, and thermal and sealing solutions.

Headquartered in Maumee, Ohio, USA, Dana reported sales of $7.5 billion in 2025. With a history dating to 1904, the company employs 27,000 people in 24 countries across six continents. Learn more at dana.com

SOURCE Dana Incorporated

Also from this source

Dana Incorporated (DAN) Presents at UBS Auto and Auto Tech Conference 2026 Transcript

Dana stock tumbled after the company agreed to combine with Eaton's mobility business, but analysts say the deal could create a stronger supplier with meaningful synergy opportunities.

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Dana Incorporated (NYSE: DAN) to Eaton Corporation plc. Upon closing of the Proposed Transaction, Dana shareholders will own approximately 49.9% of the combined company.

Halper Sadeh encourages Dana shareholders to click here to learn more about their rights and optionsor contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected].

The investigation concerns whether Dana and its board of directors violated the federal securities laws and/or breached their fiduciary duties by failing to: (1) obtain the best possible price for Dana shareholders; (2) conduct a fair sales process free of any conflicts of interests; and (3) disclose all material information for Dana shareholders to evaluate the transaction.

On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief and benefits.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260611885260/en/

Posted by Defense World Staff on Apr 7th, 2026

Allspring Global Investments Holdings LLC lessened its holdings in GATX Corporation (NYSE:GATX – Free Report) by 35.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,778 shares of the transportation company’s stock after selling 16,030 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 0.08% of GATX worth $4,916,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in GATX. Alliancebernstein L.P. boosted its holdings in GATX by 681.7% in the third quarter. Alliancebernstein L.P. now owns 574,333 shares of the transportation company’s stock worth $100,393,000 after purchasing an additional 500,857 shares during the period. Squarepoint Ops LLC boosted its holdings in GATX by 429.5% in the second quarter. Squarepoint Ops LLC now owns 187,835 shares of the transportation company’s stock worth $28,844,000 after purchasing an additional 152,361 shares during the period. Encompass Capital Advisors LLC acquired a new position in GATX in the second quarter worth $23,025,000. Steadfast Capital Management LP acquired a new position in GATX in the third quarter worth $24,489,000. Finally, Marshall Wace LLP lifted its stake in GATX by 205.4% in the second quarter. Marshall Wace LLP now owns 128,192 shares of the transportation company’s stock valued at $19,685,000 after buying an additional 86,215 shares during the last quarter. Institutional investors and hedge funds own 93.14% of the company’s stock.

GATX Stock Performance GATX stock opened at $172.81 on Tuesday. The company has a debt-to-equity ratio of 3.45, a quick ratio of 16.31 and a current ratio of 16.31. The stock has a market capitalization of $6.14 billion, a price-to-earnings ratio of 18.95 and a beta of 1.22. GATX Corporation has a 1 year low of $139.44 and a 1 year high of $199.00. The stock’s fifty day moving average is $180.17 and its two-hundred day moving average is $172.46.

GATX (NYSE:GATX – Get Free Report) last posted its earnings results on Thursday, February 19th. The transportation company reported $2.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.42 by $0.02. The company had revenue of $449.00 million for the quarter, compared to analysts’ expectations of $443.67 million. GATX had a return on equity of 11.05% and a net margin of 19.15%.The firm’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same period last year, the business posted $1.93 earnings per share. GATX has set its FY 2026 guidance at 9.500-10.100 EPS. On average, research analysts predict that GATX Corporation will post 8.5 EPS for the current year.

GATX Increases Dividend The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 31st. Stockholders of record on Monday, March 2nd were issued a dividend of $0.66 per share. This represents a $2.64 dividend on an annualized basis and a dividend yield of 1.5%. This is a positive change from GATX’s previous quarterly dividend of $0.61. The ex-dividend date of this dividend was Monday, March 2nd. GATX’s dividend payout ratio is 28.95%.

Insider Activity In other news, VP Robert Zmudka sold 5,200 shares of the firm’s stock in a transaction on Friday, February 20th. The stock was sold at an average price of $192.61, for a total transaction of $1,001,572.00. Following the transaction, the vice president directly owned 7,493 shares of the company’s stock, valued at approximately $1,443,226.73. This trade represents a 40.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Jeffery R. Young sold 2,595 shares of the firm’s stock in a transaction on Friday, February 20th. The shares were sold at an average price of $196.29, for a total value of $509,372.55. Following the transaction, the senior vice president directly owned 7,700 shares in the company, valued at $1,511,433. This trade represents a 25.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 9,795 shares of company stock valued at $1,907,525. Company insiders own 1.86% of the company’s stock.

Analysts Set New Price Targets A number of equities research analysts have issued reports on the company. Weiss Ratings reiterated a “buy (b)” rating on shares of GATX in a research note on Thursday, January 22nd. Susquehanna raised their target price on GATX from $212.00 to $220.00 and gave the company a “positive” rating in a research note on Friday, February 20th. Citigroup cut GATX from a “buy” rating to a “neutral” rating and raised their target price for the company from $197.00 to $210.00 in a research note on Tuesday, February 24th. Finally, The Goldman Sachs Group reiterated a “buy” rating and issued a $204.00 target price on shares of GATX in a research note on Wednesday, January 14th. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, GATX has a consensus rating of “Moderate Buy” and an average price target of $211.33.

View Our Latest Stock Analysis on GATX

GATX Profile (Free Report)

GATX Corporation (NYSE: GATX) is a global railcar leasing and asset management company headquartered in Chicago, Illinois. Founded in 1898 as General American Transportation Corporation, GATX has grown into one of the world’s leading lessors of railcars, marine vessels and industrial assets. The company’s core business focuses on leasing and managing high-value equipment for customers in the energy, industrial, chemical, agricultural and metals markets.

In its Rail North America segment, GATX owns and manages a diverse fleet of more than 60,000 railcars, including tank cars, covered hoppers, boxcars and flatcars.

Read More Five stocks we like better than GATX Want to see what other hedge funds are holding GATX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GATX Corporation (NYSE:GATX – Free Report).

Receive News & Ratings for GATX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GATX and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEApella Capital LLC Acquires 223,762 Shares of Vanguard Total Stock Market ETF $VTI

NEXT HEADLINE »Apella Capital LLC Raises Stock Holdings in iShares Core S&P Mid-Cap ETF $IJH

Posted by Defense World Staff on Apr 15th, 2026

GATX (NYSE:GATX – Get Free Report) is expected to be announcing its Q1 2026 results before the market opens on Wednesday, April 22nd. Analysts expect the company to announce earnings of $2.41 per share and revenue of $608.3690 million for the quarter. GATX has set its FY 2026 guidance at 9.500-10.100 EPS. Investors are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Tuesday, April 21, 2026 at 12:30 PM ET.

GATX (NYSE:GATX – Get Free Report) last posted its quarterly earnings results on Thursday, February 19th. The transportation company reported $2.44 earnings per share for the quarter, beating analysts’ consensus estimates of $2.42 by $0.02. GATX had a return on equity of 11.05% and a net margin of 19.15%.The firm had revenue of $449.00 million for the quarter, compared to the consensus estimate of $443.67 million. During the same period in the previous year, the business earned $1.93 earnings per share. The company’s revenue for the quarter was up 8.6% compared to the same quarter last year.

GATX Stock Up 0.8% GATX stock opened at $196.00 on Wednesday. The company has a debt-to-equity ratio of 3.45, a current ratio of 16.31 and a quick ratio of 16.31. GATX has a 1-year low of $140.75 and a 1-year high of $199.00. The company has a market cap of $6.96 billion, a PE ratio of 21.49 and a beta of 1.22. The stock’s 50 day moving average price is $181.06 and its 200 day moving average price is $173.08.

GATX Increases Dividend The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 31st. Investors of record on Monday, March 2nd were paid a $0.66 dividend. This represents a $2.64 dividend on an annualized basis and a dividend yield of 1.3%. This is a boost from GATX’s previous quarterly dividend of $0.61. The ex-dividend date was Monday, March 2nd. GATX’s dividend payout ratio (DPR) is presently 28.95%.

Wall Street Analysts Forecast Growth A number of analysts recently weighed in on GATX shares. Citigroup upgraded GATX from a “neutral” rating to a “buy” rating and lifted their price target for the company from $210.00 to $211.00 in a research note on Wednesday, April 8th. Susquehanna boosted their target price on GATX from $212.00 to $220.00 and gave the stock a “positive” rating in a research report on Friday, February 20th. The Goldman Sachs Group reiterated a “buy” rating and set a $204.00 target price on shares of GATX in a research report on Wednesday, January 14th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of GATX in a research report on Thursday, January 22nd. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $211.67.

Check Out Our Latest Analysis on GATX

Insider Buying and Selling In other GATX news, EVP Brian L. Glassberg sold 2,000 shares of the company’s stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $198.29, for a total transaction of $396,580.00. Following the completion of the sale, the executive vice president directly owned 7,041 shares in the company, valued at $1,396,159.89. This represents a 22.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Robert Zmudka sold 5,200 shares of the company’s stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $192.61, for a total value of $1,001,572.00. Following the sale, the vice president owned 7,493 shares of the company’s stock, valued at $1,443,226.73. This represents a 40.97% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 9,795 shares of company stock worth $1,907,525. 1.86% of the stock is owned by company insiders.

Institutional Investors Weigh In On GATX Several institutional investors and hedge funds have recently added to or reduced their stakes in GATX. Alliancebernstein L.P. increased its stake in GATX by 681.7% during the third quarter. Alliancebernstein L.P. now owns 574,333 shares of the transportation company’s stock worth $100,393,000 after acquiring an additional 500,857 shares during the last quarter. Squarepoint Ops LLC increased its stake in GATX by 429.5% during the second quarter. Squarepoint Ops LLC now owns 187,835 shares of the transportation company’s stock worth $28,844,000 after acquiring an additional 152,361 shares during the last quarter. Steadfast Capital Management LP acquired a new stake in GATX during the third quarter worth about $24,489,000. Loomis Sayles & Co. L P acquired a new stake in GATX during the fourth quarter worth about $11,198,000. Finally, Tudor Investment Corp ET AL increased its stake in GATX by 118.4% during the fourth quarter. Tudor Investment Corp ET AL now owns 118,877 shares of the transportation company’s stock worth $20,162,000 after acquiring an additional 64,454 shares during the last quarter. 93.14% of the stock is currently owned by institutional investors and hedge funds.

About GATX (Get Free Report)

GATX Corporation (NYSE: GATX) is a global railcar leasing and asset management company headquartered in Chicago, Illinois. Founded in 1898 as General American Transportation Corporation, GATX has grown into one of the world’s leading lessors of railcars, marine vessels and industrial assets. The company’s core business focuses on leasing and managing high-value equipment for customers in the energy, industrial, chemical, agricultural and metals markets.

In its Rail North America segment, GATX owns and manages a diverse fleet of more than 60,000 railcars, including tank cars, covered hoppers, boxcars and flatcars.

Further Reading Five stocks we like better than GATX

Receive News & Ratings for GATX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GATX and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINESandvik (OTCMKTS:SDVKY) Rating Lowered to “Hold” at Citigroup

NEXT HEADLINE »Wizz Air (OTCMKTS:WZZZY) Stock Rating Lowered by Sanford C. Bernstein

CHICAGO--(BUSINESS WIRE)--GATX Corporation (NYSE: GATX) today reported 2026 first-quarter net income attributable to GATX of $85.5 million, or $2.35 per diluted share, compared to net income attributable to GATX of $78.6 million, or $2.15 per diluted share, in the first quarter of 2025.

"Consistent with our expectations entering the year, our global businesses performed well in the first quarter," said Robert C. Lyons, president and chief executive officer of GATX. "Integration of the Wells Fargo rail operating lease fleet is progressing well, positioning us to serve customers with an expanded portfolio supported by our operational and commercial expertise. Beginning this quarter, commercial metrics and fleet statistics for Rail North America reflect the combined legacy and newly acquired fleets, consistent with consolidation in our financial statements. At quarter end, Rail North America's fleet utilization remained high at 98.1%, and the first-quarter renewal success rate was 79.1%, reflecting stable demand for existing railcars. The renewal lease rate change of GATX’s Lease Price Index was 22.3% with an average renewal term of 56 months. Furthermore, we generated first-quarter gains on asset dispositions of approximately $50.0 million, reflecting continued strength in the secondary market and strong asset valuations.

"At GATX Rail Europe, fleet utilization remained steady at 94.7% in the first quarter. Our European team achieved increases in renewal lease rates compared to expiring rates across the majority of car types, despite macroeconomic pressures weighing on our customers' fleet planning activities. At GATX Rail India, demand for railcars remained solid, with fleet utilization at 100.0% at quarter end.

"Within Engine Leasing, we continued to benefit from strong demand for aircraft spare engines, with solid performance across our engine portfolios in the first quarter. While we are closely monitoring developments related to the Middle East conflict and their implications for global air travel and airline financial performance, based on the resiliency the industry has demonstrated through various external events over many decades, we remain confident in the long-term strength of this business."

Mr. Lyons added, "First-quarter investment volume totaled more than $4.5 billion, including the acquisition of Wells Fargo’s rail operating lease portfolio for approximately $4.2 billion. During the quarter, we executed on attractive investment opportunities to acquire new and existing railcars across our global rail businesses."

Mr. Lyons concluded, “Our first quarter progressed largely as we anticipated. Our expanded portfolio of long‑lived assets, deep customer relationships across diverse end markets, and consistently strong cash flows position us well to navigate increased macro uncertainty. We will monitor our markets for impacts from the war in the Middle East, while continuing to execute on our disciplined growth strategy. Based on first-quarter results and our current outlook, we continue to expect 2026 full-year earnings to be $9.50–$10.10 per diluted share, excluding the impact of Tax Adjustments and Other Items.”

RAIL NORTH AMERICA

Rail North America reported segment profit of $103.9 million in the first quarter of 2026, compared to $88.8 million in the first quarter of 2025. Higher 2026 first-quarter segment profit was driven by higher lease revenue and higher gains on asset dispositions.

As of March 31, 2026, Rail North America’s fleet totaled approximately 206,100 cars, including 9,900 boxcars. The following fleet statistics and performance discussion exclude the boxcar fleet.

Fleet utilization was 98.1% at the end of the first quarter of 2026, compared to 99.0% at the end of the prior quarter and 99.2% at the end of the first quarter of 2025. At the time of the Wells Fargo acquisition, GATX Rail North American's fleet utilization was 99.0%, while Wells Fargo Rail's fleet utilization was 96.5%. Therefore, utilization of 98.1% is a byproduct of the fleet combination and consistent with expectations outlined at the beginning of this year.

During the first quarter of 2026, the renewal lease rate change of the GATX Lease Price Index (LPI) was 22.3%, compared to 21.9% in the prior quarter and 24.5% in the first quarter of 2025. The average lease renewal term for all cars included in the LPI during the first quarter of 2026 was 56 months, compared to 58 months in the prior quarter and 61 months in the first quarter of 2025. The 2026 first-quarter renewal success rate was 79.1%, compared to 91.4% in the prior quarter and 85.1% in the first quarter of 2025. Rail North America’s investment volume during the first quarter was approximately $4.5 billion, including the acquisition of Wells Fargo’s rail operating lease portfolio for approximately $4.2 billion.

Additional fleet statistics, including information on the boxcar fleet, and macroeconomic data related to Rail North America’s business are provided in the attached Supplemental Information under Rail North America Statistics.

RAIL INTERNATIONAL

Rail International’s segment profit was $31.6 million in the first quarter of 2026, compared to $25.7 million in the first quarter of 2025. Higher 2026 first-quarter segment profit was driven by more railcars on lease, higher lease rates, and changes in foreign currency exchange rates.

As of March 31, 2026, GATX Rail Europe’s (GRE) fleet consisted of over 36,600 railcars. Fleet utilization was 94.7%, compared to 94.7% at the end of the prior quarter and 95.1% at the end of the first quarter of 2025.

As of March 31, 2026, Rail India's fleet consisted of approximately 12,500 railcars. Fleet utilization was 100.0%, compared to 100.0% at the end of the prior quarter and 99.6% at the end of the first quarter of 2025.

Additional fleet statistics for GRE and Rail India are provided on the last page of this press release.

ENGINE LEASING

Engine Leasing reported segment profit of $35.3 million in the first quarter of 2026, compared to segment profit of $38.6 million in the first quarter of 2025. Comparative results were driven primarily by the timing of remarketing income, which can vary materially from quarter to quarter. The Rolls-Royce and Partners Finance affiliates invested approximately $135.0 million in aircraft spare engines during the quarter, and the investment pipeline remains robust.

COMPANY DESCRIPTION

At GATX Corporation (NYSE:GATX), we empower our customers to propel the world forward. GATX leases transportation assets including railcars, aircraft spare engines and tank containers to customers worldwide. Our mission is to provide innovative, unparalleled service that enables our customers to transport what matters safely and sustainably while championing the well-being of our employees and communities. Headquartered in Chicago, Illinois since its founding in 1898, GATX has paid a quarterly dividend, uninterrupted, since 1919.

TELECONFERENCE INFORMATION

GATX Corporation will host a teleconference to discuss its 2026 first-quarter results. Call details are as follows:

Thursday, May 7, 2026
11 a.m. Eastern Time
Domestic Dial-In: 1-800-715-9871
International Dial-In: 1-646-307-1963
Replay: 1-800-770-2030 (Domestic) or 1-609-800-9909 (International) / Access Code: 2050842

Call-in details, a copy of this press release and real-time audio access are available at www.gatx.com. Please access the call 15 minutes prior to the start time. A replay will be available on the same site starting at 2 p.m. (Eastern Time), May 7, 2026.

AVAILABILITY OF INFORMATION ON GATX'S WEBSITE

Investors and others should note that GATX routinely announces material information to investors and the marketplace using SEC filings, press releases, public conference calls, webcasts and the GATX Investor Relations website. While not all of the information that the Company posts to the GATX Investor Relations website is of a material nature, some information could be deemed to be material. Accordingly, the Company encourages investors, the media and others interested in GATX to review the information that it shares on www.gatx.com under the “Investor Relations” tab.

FORWARD-LOOKING STATEMENTS

Statements in this Earnings Release not based on historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and, accordingly, involve known and unknown risks and uncertainties that are difficult to predict and could cause our actual results, performance, or achievements to differ materially from those discussed. These include statements as to our future expectations, beliefs, plans, strategies, objectives, events, conditions, financial performance, prospects, or future events. In some cases, forward-looking statements can be identified by the use of words such as “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “outlook,” “continue,” “likely,” “will,” “would”, and similar words and phrases. Forward-looking statements are necessarily based on estimates and assumptions that, while considered reasonable by us and our management, are inherently uncertain. Accordingly, you should not place undue reliance on forward-looking statements, which speak only as of the date they are made, and are not guarantees of future performance. We do not undertake any obligation to publicly update or revise these forward-looking statements, except to the extent required by applicable law.

The following factors, in addition to those discussed in our press releases and filings with the U.S. Securities and Exchange Commission, could cause actual results to differ materially from our current expectations expressed in forward-looking statements:

GATX CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)

(In millions, except per share data)

  Three Months Ended

March 31

2026

2025

Revenues

Lease revenue

$

518.7

$

359.6

Non-dedicated engine revenue

22.1

21.5

Other revenue

42.9

40.5

Total Revenues

583.7

421.6

Expenses

Maintenance expense

140.7

103.5

Depreciation expense

169.2

103.6

Operating lease expense

7.4

7.6

Other operating expense

21.8

16.0

Selling, general and administrative expense

71.3

56.6

Total Expenses

410.4

287.3

Other Income (Expense)

Net gain on asset dispositions

51.0

33.4

Interest expense, net

(151.0

)

(94.9

)

Other income (expense)

6.2

(2.7

)

Income before Income Taxes and Share of Affiliates’ Earnings

79.5

70.1

Income taxes

(21.2

)

(16.6

)

Share of affiliates’ earnings, net of taxes

20.8

25.1

Net Income

79.1

78.6

Less: Net Loss Attributable to Non-Controlling Interest

(6.4

)

—

Net Income Attributable to GATX

$

85.5

$

78.6

Share Data

Basic earnings per share

$

2.35

$

2.15

Average number of common shares

35.7

35.9

Diluted earnings per share

$

2.35

$

2.15

Average number of common shares and common share equivalents

35.8

36.0

Dividends declared per common share

$

0.66

$

0.61

  GATX CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS (UNAUDITED)

(In millions)

  March 31

December 31

2026

2025

Assets

Cash and Cash Equivalents

$

740.9

$

743.0

Restricted Cash

0.1

4,241.9

Receivables

Rent and other receivables

162.7

109.0

Finance leases (as lessor)

192.2

104.2

Less: allowance for losses

(6.1

)

(6.0

)

348.8

207.2

Operating Assets and Facilities

19,780.9

15,662.6

Less: allowance for depreciation

(4,328.3

)

(4,251.7

)

15,452.6

11,410.9

Lease Assets (as lessee)

Right-of-use assets, net of accumulated depreciation

134.7

137.4

Investments in Affiliated Companies

752.4

732.3

Goodwill

124.6

126.3

Other Assets

390.1

400.5

Total Assets

$

17,944.2

$

17,999.5

Liabilities and Equity

Accounts Payable and Accrued Expenses

$

278.7

$

318.4

Debt

Borrowings under bank credit facilities

49.7

82.2

Recourse debt

12,427.3

12,451.7

12,477.0

12,533.9

Lease Obligations (as lessee)

Operating leases

150.9

154.3

Deferred Income Taxes

1,215.6

1,195.7

Other Liabilities

165.8

162.1

Total Liabilities

14,288.0

14,364.4

Total GATX Shareholders’ Equity

2,778.1

2,750.5

Non-Controlling Interest

878.1

884.6

Total Equity

3,656.2

3,635.1

Total Liabilities and Equity

$

17,944.2

$ 

17,999.5 

  GATX CORPORATION AND SUBSIDIARIES

SEGMENT DATA (UNAUDITED)

Three Months Ended March 31, 2026

(In millions)

  Rail North
America

Rail
International

Engine
Leasing

Other

GATX
Consolidated

Revenues

Lease revenue

$

400.7

$

100.4

$

9.5

$

8.1

$

518.7

Non-dedicated engine revenue

—

—

22.1

—

22.1

Other revenue

36.0

4.8

—

2.1

42.9

Total Revenues

436.7

105.2

31.6

10.2

583.7

Expenses

Maintenance expense

120.6

19.1

—

1.0

140.7

Depreciation expense

126.7

27.8

10.6

4.1

169.2

Operating lease expense

7.4

—

—

—

7.4

Other operating expense

13.1

5.3

3.1

0.3

21.8

Total Expenses

267.8

52.2

13.7

5.4

339.1

Other Income (Expense)

Net gain on asset dispositions

49.8

1.1

—

0.1

51.0

Interest (expense) income, net

(114.0

)

(25.0

)

(13.3

)

1.3

(151.0

)

Other (expense) income

(0.8

)

2.5

3.1

1.4

6.2

Share of affiliates' pre-tax earnings

—

—

27.6

—

27.6

Segment Profit

$

103.9

$

31.6

$

35.3

$

7.6

$

178.4

Less:

Selling, general and administrative expense

71.3

Income taxes (includes $6.8 related to affiliates' earnings)

28.0

Net Income

79.1

Less: Net Loss Attributable to Non-Controlling Interest

(6.4

)

Net Income Attributable to GATX

$

85.5

Selected Data:

Investment volume

$

4,464.2

$

47.4

$

0.2

$

8.2

$

4,520.0

Net Gain on Asset Dispositions

Asset Remarketing Income:

Net gains on disposition of owned assets

$

44.0

$

—

$

—

$

0.1

$

44.1

Residual sharing income

0.1

—

—

—

0.1

Non-remarketing net gains (1)

7.4

1.1

—

—

8.5

Asset impairments

(1.7

)

—

—

—

(1.7

)

$

49.8

$

1.1

$

—

$

0.1

$

51.0

  _________

(1) Includes net gains from scrapping of railcars.

  GATX CORPORATION AND SUBSIDIARIES

SEGMENT DATA (UNAUDITED)

Three Months Ended March 31, 2025

(In millions)

  Rail North
America

Rail
International

Engine
Leasing

Other

GATX
Consolidated

Revenues

Lease revenue

$

260.0

$

83.6

$

8.1

$

7.9

$

359.6

Non-dedicated engine revenue

—

—

21.5

—

21.5

Other revenue

33.3

4.9

—

2.3

40.5

Total Revenues

293.3

88.5

29.6

10.2

421.6

Expenses

Maintenance expense

83.7

18.5

—

1.3

103.5

Depreciation expense

70.4

20.1

9.4

3.7

103.6

Operating lease expense

7.6

—

—

—

7.6

Other operating expense

7.5

4.6

2.8

1.1

16.0

Total Expenses

169.2

43.2

12.2

6.1

230.7

Other Income (Expense)

Net gain on asset dispositions

32.1

1.3

—

—

33.4

Interest (expense) income, net

(64.7

)

(19.1

)

(12.2

)

1.1

(94.9

)

Other (expense) income

(2.7

)

(1.8

)

—

1.8

(2.7

)

Share of affiliates' pre-tax earnings

—

—

33.4

—

33.4

Segment Profit

$

88.8

$

25.7

$

38.6

$

7.0

$

160.1

Less:

Selling, general and administrative expense

56.6

Income taxes (includes $8.3 related to affiliates' earnings)

24.9

Net Income

78.6

Less: Net Income Attributable to Non-Controlling Interest

—

Net Income Attributable to GATX

$

78.6

Selected Data:

Investment volume

$

227.7

$

62.7

$

—

$

5.9

$

296.3

Net Gain on Asset Dispositions

Asset Remarketing Income:

Net gains on disposition of owned assets

$

30.5

$

0.6

$

—

$

—

$

31.1

Residual sharing income

0.1

—

—

—

0.1

Non-remarketing net gains (1)

5.1

0.7

—

—

5.8

Asset impairments

(3.6

)

—

—

—

(3.6

)

$

32.1

$

1.3

$

—

$

—

$

33.4

  __________

(1) Includes net gains from scrapping of railcars.

  GATX CORPORATION AND SUBSIDIARIES

SUPPLEMENTAL INFORMATION (UNAUDITED)

(In millions, except leverage)

  3/31/2026

12/31/2025

9/30/2025

6/30/2025

3/31/2025

Total Assets, Excluding Cash, by Segment

Rail North America

$

12,242.6

$

7,969.0

$

7,865.3

$

7,886.8

$

7,888.3

Rail International

2,738.0

2,825.1

2,522.9

2,514.9

2,304.3

Engine Leasing

1,805.3

1,786.9

1,805.9

1,626.5

1,619.8

Other

417.3

433.6

415.3

416.8

396.3

Total Assets, excluding cash

$

17,203.2

$

13,014.6

$

12,609.4

$

12,445.0

$

12,208.7

Debt and Lease Obligations, Net of Unrestricted Cash

Unrestricted cash

$

(740.9

)

$

(743.0

)

$

(696.1

)

$

(754.6

)

$

(757.2

)

Borrowings under bank credit facilities

49.7

82.2

117.3

106.1

101.5

Recourse debt

12,427.3

12,451.7

8,751.3

8,741.3

8,653.1

Operating lease obligations

150.9

154.3

160.7

168.4

174.4

Total debt and lease obligations, net of unrestricted cash

$

11,887.0

$

11,945.2

$

8,333.2

$

8,261.2

$

8,171.8

Total recourse debt (1)

$

11,887.0

$

11,945.2

$

8,333.2

$

8,261.2

$

8,171.8

Total equity

$

3,656.2

$

3,635.1

$

2,718.9

$

2,669.7

$

2,549.4

Recourse Leverage (2)

3.3

3.3

3.1

3.1

3.2

Reconciliation of Total Assets to Total Assets, Excluding Cash

Total Assets

$

17,944.2

$

17,999.5

$

13,305.8

$

13,200.2

$

12,966.3

Less: cash

(741.0

)

(4,984.9

)

(696.4

)

(755.2

)

(757.6

)

Total Assets, excluding cash

$

17,203.2

$

13,014.6

$

12,609.4

$

12,445.0

$

12,208.7

  GATX CORPORATION AND SUBSIDIARIES

SUPPLEMENTAL INFORMATION (UNAUDITED)

(Continued)

  3/31/2026

12/31/2025

9/30/2025

6/30/2025

3/31/2025

Rail North America Statistics

Lease Price Index (LPI) (1)

Average renewal lease rate change

22.3

%

21.9

%

22.8

%

24.2

%

24.5

%

Average renewal term (months)

56

58

60

60

61

Renewal Success Rate (2)

79.1

%

91.4

%

87.1

%

84.2

%

85.1

%

Fleet Rollforward (3)

Beginning balance

100,593

101,288

102,317

103,310

102,966

Railcars added

98,535

920

366

595

1,464

Railcars scrapped

(1,355

)

(898

)

(478

)

(614

)

(316

)

Railcars sold

(1,540

)

(717

)

(917

)

(974

)

(804

)

Ending balance

196,233

100,593

101,288

102,317

103,310

Utilization

98.1

%

99.0

%

98.9

%

99.2

%

99.2

%

Average active railcars

193,195

99,999

100,896

102,073

102,367

Boxcar Fleet Rollforward

Beginning balance

7,032

7,478

7,621

7,990

8,395

Railcars added

3,411

1

172

27

—

Railcars scrapped

(266

)

(365

)

(285

)

(396

)

(405

)

Railcars sold

(289

)

(82

)

(30

)

—

—

Ending balance

9,888

7,032

7,478

7,621

7,990

Utilization

97.6

%

97.1

%

96.9

%

98.7

%

99.8

%

Average active railcars

9,895

7,206

7,391

7,773

8,163

Rail North America Industry Statistics

Manufacturing Capacity Utilization Index (4)

75.7

%

75.7

%

76.1

%

77.8

%

77.6

%

Year-over-year Change in U.S. Carloadings (excl. intermodal) (5)

4.2

%

1.5

%

2.1

%

2.4

%

0.1

%

Year-over-year Change in U.S. Carloadings (chemical) (5)

3.8

%

0.8

%

1.5

%

1.6

%

2.0

%

Year-over-year Change in U.S. Carloadings (petroleum) (5)

7.3

%

(1.6

)%

(1.2

)%

(0.9

)%

1.9

%

Production Backlog at Railcar Manufacturers (6)

23,128

23,431

25,687

29,871

31,548

_________

(1)

GATX's Lease Price Index (LPI) is an internally-generated business indicator that measures renewal activity for our North American railcar fleet, excluding boxcars. The LPI calculation includes all renewal activity based on a 12-month trailing average, and the renewals are weighted by the count of all renewals over the 12-month period. The average renewal lease rate change is reported as the percentage change between the average renewal lease rate and the average expiring lease rate. The average renewal lease term is reported in months and reflects the average renewal lease term in the LPI.

(2)

The renewal success rate represents the percentage of railcars on expiring leases that were renewed with the existing lessee. The renewal success rate is an important metric because railcars returned by our customers may remain idle or incur additional maintenance and freight costs prior to being leased to new customers.

(3)

Excludes boxcar fleet.

(4)

As reported and revised by the Federal Reserve.

(5)

As reported by the Association of American Railroads (AAR).

(6)

As reported by the Railway Supply Institute (RSI).

  GATX CORPORATION AND SUBSIDIARIES

SUPPLEMENTAL INFORMATION (UNAUDITED)

(Continued)

  3/31/2026

12/31/2025

9/30/2025

6/30/2025

3/31/2025

Rail Europe Statistics

Fleet Rollforward

Beginning balance

36,484

30,572

30,492

30,223

30,027

Railcars added

355

6,145

328

579

446

Railcars scrapped or sold

(188

)

(233

)

(248

)

(310

)

(250

)

Ending balance

36,651

36,484

30,572

30,492

30,223

Utilization

94.7

%

94.7

%

93.7

%

93.3

%

95.1

%

Average active railcars

34,588

32,671

28,592

28,572

28,823

Rail India Statistics

Fleet Rollforward

Beginning balance

12,165

11,712

11,112

10,895

10,583

Railcars added

343

453

600

217

312

Ending balance

12,508

12,165

11,712

11,112

10,895

Utilization

100.0

%

100.0

%

100.0

%

99.6

%

99.6

%

Average active railcars

12,275

11,905

11,363

10,945

10,711

MarketBeat Instant News Alerts

2 hours ago

Amkor Technology Target of Unusually Large Options Trading (NASDAQ:AMKR)MarketBeat

Amkor Technology, Inc. (NASDAQ:AMKR - Get Free Report) was the recipient of unusually large options trading on Friday. Investors acquired 12,436 call options on the company. This is an increase of approximately 48% compared to the average volume of 8,425 call options.

NASDAQ:AMKR

Read Amkor Technology Target of Unusually Large Options Trading (NASDAQ:AMKR)

3 hours ago

CocaCola (NYSE:KO) EVP Jennifer Mann Sells 23,984 SharesMarketBeat

CocaCola Company (The) (NYSE:KO - Get Free Report) EVP Jennifer Mann sold 23,984 shares of the firm's stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $83.41, for a total value of $2,000,505.44. Following the completion of the transaction, the executive vice president owned 157,400 shares of the company's stock, valued at approximately $13,128,734. The trade was a 13.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

NYSE:KO

Read CocaCola (NYSE:KO) EVP Jennifer Mann Sells 23,984 Shares

Trending News All MarketBeat Instant News Alerts Sort By

Time Frame

Alert Type

Keywords

Page 1 of 324

Get 30 Days of MarketBeat All Access for Free

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.

Start Your 30-Day Trial

Sign in to your free account to enjoy these benefits

In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer.

Shares of CONMED Corporation (NYSE: CNMD - Get Free Report) have earned an average rating of "Reduce" from the eight analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and seven have issued a hold recommendation on the company. The average 12 month price

Key Takeaways CONMED growth is driven by AirSeal, Buffalo Filter, and BioBrace platforms, gaining adoption.CNMD benefits from supply-chain recovery, boosting orthopedic sales and product availability.CONMED expects margin gains from GI exit, despite tariff and revenue headwinds in 2026. CONMED Corporation (CNMD - Free Report) is well-positioned for growth on the back of rising adoption of its high-margin, differentiated platforms like AirSeal, Buffalo Filter and BioBrace. The company’s long-term prospects seem good as robotic procedure volume rises, coupled with the expanding penetration of Ambulatory Surgery Centers. Moreover, improving supply-chain bottlenecks should drive top- and bottom-line growth.

CONMED is facing tariff headwinds that are unfavorably impacting its earnings per share (EPS) and revenue expansion. Higher operating expense investments remain a concern.

Shares of this Zacks Rank #3 (Hold) company have lost 9.9% in the year-to-date period compared with the industry’s 3.3% decline and the S&P 500 Index’s 3.6% fall.

CONMED, a renowned global medical products manufacturer specializing in surgical instruments and devices, has a market capitalization of $1.06 billion. The company projects 5.2% earnings growth over the next five years.

The company’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.56%.

Image Source: Zacks Investment Research

Factors Favoring CNMD StockStrong Growth Drivers in High-Margin Segment: CONMED delivered a strong fourth-quarter fiscal 2025 performance, led by robust orthopedic growth, solid execution and continued expansion of its higher-margin platforms. Looking ahead to fiscal 2026, management plans to stay focused on three key growth drivers, AirSeal insufflation systems, Buffalo Filter and BioBrace, which offer favorable procedural growth and margin profiles. AirSeal remains significantly underpenetrated in traditional laparoscopy, currently used in just 6–7% of the more than 3 million annual U.S. procedures, leaving ample room for long-term expansion as adoption improves.

Buffalo Filter continues to benefit from a growing global smoke evacuation market exceeding $1 billion, supported by increasing regulatory mandates such as smoke-free operating room laws across multiple U.S. states, as well as adoption in Nordic countries and Canada. Meanwhile, BioBrace is gaining traction across more than 70 surgical applications, with new product innovations and ongoing clinical validation strengthening its adoption. Collectively, these platforms underscore CONMED’s strategy to prioritize R&D, commercial execution and capital allocation toward high-growth, high-margin opportunities.

Supply-Chain Normalization Boosting Orthopedics Recovery: Resolving the sports medicine supply-chain constraints remains a central operational priority entering fiscal 2026. During fiscal 2025, the company invested in additional planning capabilities, infrastructure, external operational expertise and leadership resources, including back-order levels and the number of affected SKUs declining to a three-year low by year-end.

This improvement enabled the orthopedics segment to return to stronger growth, with fourth-quarter orthopedic sales rising 12.1% in constant currency, reflecting both improving product availability and continued demand for key offerings such as BioBrace and other soft-tissue repair solutions.

Management’s near-term objective is to stabilize and scale supply processes to ensure consistent product availability, while the long-term objective is to build a more agile, data-driven, high-performance supply chain to support sustained innovation and above-market growth in the orthopedic portfolio over time.

Margin Improvement Initiatives and Capital Returns: Several structural actions underway are expected to strengthen profitability and shareholder returns beginning in fiscal 2026 and continuing thereafter. The strategic exit from the gastroenterology product lines is intended to concentrate resources on higher-growth, higher-margin businesses. It is expected to improve the company’s consolidated long-term gross margin profile by 80 basis points (bps) once the transition is completed.

For fiscal 2026, CONMED guided to an additional 50 to 100 bps of gross-margin expansion, driven by favorable product mix and cost improvements. The company suspended its dividend and authorized a $150 million share repurchase program, with management indicating that redeploying the prior dividend amount toward buybacks is expected to contribute 7 cents of EPS accretion in fiscal 2026, supporting ongoing capital-return priorities while maintaining flexibility to invest in innovation and growth initiatives.

Downsides of CNMD StockRevenue & EPS Headwinds From GI Exit and Tariffs: While CNMD is positioning itself for stronger long-term growth and profitability, near-term challenges tied to strategic portfolio changes and external cost pressures remain. Management expects fiscal 2026 revenue growth to be moderate, with constant-currency organic growth of 4.5% to 6%, impacted by the shift away from lower-priority product lines. U.S. general surgery performance has also been affected by portfolio rationalization, including the exit of select smaller products, reduced focus on OEM smoke-evacuation offerings and the broader exit from the gastroenterology business.

Adjusted EPS is projected to be in the range of $4.30 to $4.45, down from $4.59 in fiscal 2025, reflecting a 45–50 cent hit from the GI exit and an additional 30–35 cent drag from tariff-related costs. Despite these pressures, management views the GI exit as a strategic move to enhance long-term margins and prioritize higher-growth areas.

Rising Operating Expense Investments: Operating expenses are anticipated to increase in fiscal 2026 as the company ramps up investments to drive its core growth platforms and strengthen its innovation pipeline. Adjusted SG&A expenses are expected to reach 38% to 38.5% of sales, influenced by lower revenues following the exit of the GI portfolio and higher commercial spending to support the expansion of key surgical and orthopedic businesses. Meanwhile, R&D spending is projected to rise to 4.5% to 5% of sales, marking an increase from previous years as CNMD allocates more resources toward product development, clinical research and technological advancements in areas such as robotic and laparoscopic surgery, smoke evacuation and soft-tissue repair.

Estimate TrendCONMED is witnessing a stable estimate revision trend for fiscal 2026. In the past 60 days, the Zacks Consensus Estimate for earnings has remained stable at $4.36 per share.

The Zacks Consensus Estimate for first-quarter fiscal 2026 revenues and EPS is pegged at $310.7 million and 82 cents, respectively, suggesting 3.3% and 13.7% declines from the year-ago reported numbers.

Stocks to ConsiderSome better-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , GE HealthCare Technologies (GEHC - Free Report) and Cardinal Health (CAH - Free Report) .

Phibro Animal Health, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter fiscal 2026 adjusted EPS of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.

PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.

GE HealthCare Technologies, currently carrying a Zacks Rank #2 (Buy), reported fourth-quarter 2025 adjusted EPS of $1.44, which surpassed the Zacks Consensus Estimate by 0.7%. Revenues of $5.7 billion beat the Zacks Consensus Estimate by 1.9%.

GEHC has an estimated long-term earnings growth rate of 9.1% compared with the industry’s 12% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 7.5%.

Cardinal Health, currently carrying a Zacks Rank #2, reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.

CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.3% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2026.

First Quarter 2026 Highlights

Sales of $317.0 million decreased 1.3% year-over-year as reported and 2.9% in constant currency. Net sales growth was impacted by a $15.5 million decrease in sales from the exit of certain GI products. Domestic revenue decreased 5.8% year-over-year. Domestic sales growth was impacted by a $15.2 million decrease in sales from the exit of certain GI products. International revenue increased 4.7% year-over-year as reported and 1.0% in constant currency. International sales growth was impacted by a $0.3 million decrease in sales from the exit of certain GI products. Diluted net earnings per share (GAAP) were $0.45, compared to diluted net earnings per share (GAAP) of $0.19 in the first quarter of 2025. Adjusted diluted net earnings per share(1) were $0.89, compared to adjusted diluted net earnings per share of $0.95 in the first quarter of 2025. “Our 2025 momentum continued in the first quarter as we delivered revenue and adjusted earnings ahead of our expectations,” said Patrick J. Beyer, CONMED’s President and Chief Executive Officer. “We continue to concentrate our resources and investment on our higher-growth, higher-margin areas: minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair.”

2026 Outlook

Based on the Company’s first quarter performance, management is raising its outlook for full-year 2026 organic revenue growth on a constant currency basis. The Company now expects year-over-year organic constant currency revenue growth, which excludes gastroenterology product sales, of approximately 5.0% to 6.5% compared to the prior guidance range of 4.5% to 6.0%. Full-year 2026 reported revenue is now expected to be in the range of $1.350 billion to $1.375 billion, compared to prior guidance of $1.345 billion to $1.375 billion. The updated revenue outlook reflects an estimated 40 to 50 basis points of favorable foreign exchange impact, compared to the prior assumption of 0 to 50 basis points of favorable impact. This updated guidance also reflects an estimated $14.5 million to $17.5 million in revenue from gastroenterology products, reduced from the prior guidance of $21.0 million to $25.0 million due to the divestiture of the remaining gastroenterology portfolio.

The Company continues to expect full-year adjusted diluted net earnings per share(2) in the range of $4.30 to $4.45. The reaffirmed outlook reflects stronger underlying operating performance, largely offset by higher-than-previously anticipated interest expense due to the planned refinancing of the Company's debt during 2026.

Supplemental Financial Disclosures

(1) A reconciliation of reported diluted net earnings per share to adjusted diluted net earnings per share, a non-GAAP financial measure, appears below.

(2) Information reconciling forward-looking adjusted diluted net earnings per share to the comparable GAAP financial measures is unavailable to the company without unreasonable effort, as discussed below.

Conference Call

The Company’s management will host a conference call today at 4:30 p.m. ET to discuss its first quarter 2026 results.

To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode.

This conference call will also be webcast and can be accessed from the “Investors” section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

Consolidated Condensed Statements of Income

(in thousands except per share amounts, unaudited)

Three Months Ended

March 31,

2026

2025

Net sales

$

317,046

$

321,256

Cost of sales

133,599

143,504

Gross profit

183,447

177,752

% of sales

57.9

%

55.3

%

Selling & administrative expense

141,699

148,847

Research & development expense

16,333

12,947

Income from operations

25,415

15,958

% of sales

8.0

%

5.0

%

Interest expense

7,060

8,286

Income before income taxes

18,355

7,672

Provision for income taxes

4,527

1,636

Net income

$

13,828

$

6,036

Basic EPS

$

0.45

$

0.19

Diluted EPS

0.45

0.19

Basic shares

30,588

30,973

Diluted shares

30,621

31,151

Sales Summary

(in millions, unaudited)

Three Months Ended March 31,

% Change

Domestic

International

2026

2025

As

Reported

Impact of

Foreign

Currency

Constant

Currency

As

Reported

As

Reported

Impact of

Foreign

Currency

Constant

Currency

Orthopedic Surgery

$

147.7

$

138.3

6.8

%

-2.3

%

4.5

%

5.5

%

7.6

%

-3.7

%

3.9

%

General Surgery

169.3

183.0

-7.4

%

-1.1

%

-8.5

%

-10.4

%

0.1

%

-3.9

%

-3.8

%

$

317.0

$

321.3

-1.3

%

-1.6

%

-2.9

%

-5.8

%

4.7

%

-3.7

%

1.0

%

Single-use Products

$

270.0

$

276.3

-2.3

%

-1.6

%

-3.9

%

-8.1

%

6.2

%

-4.0

%

2.2

%

Capital Products

47.0

45.0

4.6

%

-1.5

%

3.1

%

12.4

%

-2.0

%

-2.8

%

-4.8

%

$

317.0

$

321.3

-1.3

%

-1.6

%

-2.9

%

-5.8

%

4.7

%

-3.7

%

1.0

%

Domestic

$

173.0

$

183.8

-5.8

%

0.0

%

-5.8

%

International

144.0

137.5

4.7

%

-3.7

%

1.0

%

$

317.0

$

321.3

-1.3

%

-1.6

%

-2.9

%

Reconciliation of Reported Net Income to Adjusted Net Income

(in thousands, except per share amounts, unaudited)

Three Months Ended March 31, 2026

Gross Profit

Selling & Administrative Expense

Research & Development Expense

Operating Income

Interest Expense

Tax Expense

Effective Tax Rate

Net Income

Diluted EPS

As reported

$

183,447

$

141,699

$

16,333

$

25,415

$

7,060

$

4,527

24.7

%

$

13,828

$

0.45

% of sales

57.9

%

44.7

%

5.2

%

8.0

%

Operational optimization costs(1)

379

(7,526

)

-

7,905

-

1,801

6,104

Executive transition costs(2)

-

(3,342

)

-

3,342

-

761

2,581

EU medical device regulations(3)

-

-

(1,167

)

1,167

-

266

901

Contingent consideration fair value adjustments(4)

-

(722

)

-

722

-

164

558

Termination of distribution agreement(5)

(1,864

)

-

-

(1,864

)

-

(425

)

(1,439

)

Gain on sale of product line(6)

-

3,916

-

(3,916

)

-

(892

)

(3,024

)

$

181,962

$

134,025

$

15,166

$

32,771

$

7,060

$

6,202

$

19,509

Adjusted gross profit %

57.4

%

Amortization(7)

$

1,500

(7,261

)

-

8,761

(1,276

)

2,442

7,595

As adjusted

$

126,764

$

15,166

$

41,532

$

5,784

$

8,644

24.2

%

$

27,104

$

0.89

% of sales

40.0

%

4.8

%

13.1

%

Three Months Ended March 31, 2025

Gross Profit

Selling & Administrative Expense

Research & Development Expense

Operating Income

Interest Expense

Tax Expense

Effective Tax Rate

Net Income

Diluted EPS

As reported

$

177,752

$

148,847

$

12,947

$

15,958

$

8,286

$

1,636

21.3

%

$

6,036

$

0.19

% of sales

55.3

%

46.3

%

4.0

%

5.0

%

Operational optimization costs(1)

3,410

(490

)

-

3,900

-

901

2,999

Executive transition costs(2)

-

(12,165

)

-

12,165

-

2,812

9,353

Contingent consideration fair value adjustments(4)

-

(3,962

)

-

3,962

-

916

3,046

Gain on sale of product line(6)

-

354

-

(354

)

-

(82

)

(272

)

Legal matters(8)

-

(1,037

)

-

1,037

-

240

797

$

181,162

$

131,547

$

12,947

$

36,668

$

8,286

$

6,423

$

21,959

Adjusted gross profit %

56.4

%

Amortization(7)

$

1,500

(7,172

)

-

8,672

(1,443

)

2,455

7,660

As adjusted

$

124,375

$

12,947

$

45,340

$

6,843

$

8,878

23.1

%

$

29,619

$

0.95

% of sales

38.7

%

4.0

%

14.1

%

Reconciliation of Reported Net Income to EBITDA & Adjusted EBITDA

(in thousands, unaudited)

Three Months Ended

March 31,

2026

2025

Net income

$

13,828

$

6,036

Provision for income taxes

4,527

1,636

Interest expense

7,060

8,286

Depreciation

4,174

4,235

Amortization

14,663

14,018

EBITDA

$

44,252

$

34,211

Stock based compensation

4,783

6,381

Operational optimization costs

7,905

3,900

Executive transition costs

3,342

12,165

EU medical device regulations

1,167

-

Contingent consideration fair value adjustments

722

3,962

Termination of distribution agreement

(1,864

)

-

Gain on sale of product line

(3,916

)

(354

)

Legal matters

-

1,037

Adjusted EBITDA

$

56,391

$

61,302

EBITDA Margin

EBITDA

14.0

%

10.6

%

Adjusted EBITDA

17.8

%

19.1

%

About CONMED Corporation

CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, and thoracic surgery. For more information, visit www.conmed.com.

Forward-Looking Statements

This press release and associated conference call may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2025 and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.

Supplemental Information - Reconciliation of GAAP to Non-GAAP Financial Measures

The Company supplements the reporting of its financial information determined under generally accepted accounting principles in the United States (GAAP) with certain non-GAAP financial measures, including percentage sales growth in constant currency; adjusted gross profit; cost of sales excluding specified items; adjusted selling and administrative expenses; adjusted research and development expense; adjusted operating income; adjusted interest expense; adjusted income tax expense; adjusted effective income tax rate; adjusted net income and adjusted diluted net earnings per share (EPS). The Company believes that these non-GAAP measures provide meaningful information to assist investors and shareholders in understanding its financial results and assessing its prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are important indicators of its operations because they exclude items that may not be indicative of, or are unrelated to, its core operating results and provide a baseline for analyzing trends in the Company’s underlying business. Further, the presentation of EBITDA is a non-GAAP measurement that management considers useful for measuring aspects of the Company’s cash flow. Management uses these non-GAAP financial measures for reviewing the operating results and analyzing potential future business trends in connection with its budget process and bases certain management incentive compensation on these non-GAAP financial measures.

Net sales on a constant currency basis is a non-GAAP measure. The Company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. To measure percentage sales growth in constant currency, the Company removes the impact of changes in foreign currency exchange rates that affect the comparability and trend of net sales. To measure earnings performance on a consistent and comparable basis, the Company excludes certain items that affect the comparability of operating results and the trend of earnings. These adjustments are irregular in timing, may not be indicative of past and future performance and are therefore excluded to allow investors to better understand underlying operating trends.

Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales growth, gross profit, cost of sales, selling and administrative expenses, research and development expense, operating income, interest expense, income tax expense, effective income tax rate, net income and diluted net earnings per share, the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures above, provide a more complete understanding of the business. The Company strongly encourages investors and shareholders to review its financial statements and publicly filed reports in their entirety and not to rely on any single financial measure.

We are unable to present a quantitative reconciliation of our expected diluted net earnings per share to expected adjusted diluted net earnings per share as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of acquisition, integration and other charges. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our consolidated condensed statements of income.

For the quarter ended March 2026, Conmed (CNMD - Free Report) reported revenue of $317.05 million, down 1.3% over the same period last year. EPS came in at $0.89, compared to $0.95 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $310.7 million, representing a surprise of +2.04%. The company delivered an EPS surprise of +8.98%, with the consensus EPS estimate being $0.82.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Conmed performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Geographic Revenue- International: $144 million versus the two-analyst average estimate of $137.8 million. The reported number represents a year-over-year change of +4.7%.Geographic Revenue- Domestic: $173 million versus $172.91 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -5.9% change.Net Sales- Single-use Products: $270 million versus $266.61 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -2.3% change.Net Sales- General Surgery: $169.3 million compared to the $170.48 million average estimate based on two analysts. The reported number represents a change of -7.5% year over year.Net Sales- Orthopedic Surgery: $147.7 million compared to the $140.22 million average estimate based on two analysts. The reported number represents a change of +6.8% year over year.Net Sales- Capital Products: $47 million compared to the $44.09 million average estimate based on two analysts. The reported number represents a change of +4.4% year over year.View all Key Company Metrics for Conmed here>>>

Shares of Conmed have returned +4% over the past month versus the Zacks S&P 500 composite's +12.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Key Takeaways CONMED beat Q1 EPS and revenue estimates, though sales dipped 1.3% year over year.CNMD raised its 2026 organic CER revenue growth outlook to 5-6.5% on stronger execution.CNMD saw orthopedic growth offset by GI product exit, which hurt general surgery sales. CONMED Corporation (CNMD - Free Report) posted adjusted earnings per share (EPS) of 89 cents for the first quarter of 2026, down 6.3% year over year. The figure beat the Zacks Consensus Estimate by 8.5%.

The adjustments include costs related to legal matters and contingent consideration fair value adjustments, among others.

GAAP EPS for the quarter was 45 cents, up 136.8% from the year-ago period’s EPS of 19 cents.

CNMD’s Revenues in DetailCONMED registered revenues of $317 million in the first quarter, down 1.3% year over year on a reported basis. The figure beat the Zacks Consensus Estimate by 2%.

At the constant exchange rate (CER), revenues were up 2.9% year over year.

Per management, the top line was hurt by a $15.5 million decrease in sales from the exit of certain GI products.

CONMED’s Segmental DetailsCNMD derived its revenues from two product lines — Orthopedic Surgery and General Surgery.

Orthopedic Surgery revenues in the fourth quarter totaled $147.7 million, up 6.8% and 4.5% year over year on a reported basis and at CER, respectively.

The U.S. Orthopedic sales grew 5.5%. Internationally, orthopedic sales increased 7.6% and 3.9% on a reported basis and at CER, respectively.

General Surgery revenues were $169.3 million, down 7.4% on a reported basis and 8.5% at CER year over year.

U.S. General Surgery sales declined 10.4%, while internationally General Surgery sales increased 0.1% but declined 3.8% on a reported basis and at CER, respectively.

The decline in the United States was due to a loss of $15.2 million in sales due to the exit of certain GI products.

CNMD’s Geographical ResultsDomestic revenues in the first quarter totaled $173 million, down 5.8% on a reported basis year over year.

International revenues in the first quarter amounted to $144 million, up 4.7% on a reported basis and 1% at CER year over year.

CONMED’s Margin AnalysisIn the quarter under review, CNMD’s adjusted gross profit increased 0.4% year over year to $181.9 million. The gross margin expanded 100 basis points (bps) to 57.4%.

Selling & administrative expenses decreased 4.8% year over year to $141.7 million. Research and development expenses rose 26.2% to $16.3 million. Total operating expenses of $158 million decreased 2.3% on a year-over-year basis.

Total adjusted operating profit totaled $32.8 million, reflecting a 10.6% decrease from the year-ago quarter. The operating margin in the first quarter contracted 100 bps to 13.1%.

CNMD’s Financial PositionThe company exited the reported quarter with cash and cash equivalents of $35 million compared with $40.8 million a year ago.

Cumulative net cash provided by operating activities at the end of first-quarter 2026 was $13.5 million compared with $41.5 million a year ago.

CONMED’s GuidanceCNMD has updated its outlook for 2026.

For 2026, total reported revenues are expected to be in the range of $1,350 million-$1,375 million compared with previous guidance of $1,345 million-$1,375 million. The Zacks Consensus Estimate is pegged at $1.36 billion.

Organic CER revenues are expected to lie between $1,331.2 million and $1,350.1 million, reflecting organic CER growth of 5-6.5% over the comparable 2025 period. The company previously expected Organic CER revenues of $1,324 million to $1,344 million.

The company continues to expect adjusted EPS for 2026 in the range of $4.30-$4.45. The Zacks Consensus Estimate is pegged at $4.36.

CONMED expects revenues to be in the range of $336 million-$340 million for the second quarter. The Zacks Consensus Estimate is pegged at $310.7 million.

Our Take on CNMDCONMED exited the first quarter of 2026 with better-than-expected results. CONMED’s results highlight a strategic reset that should underpin performance through the remainder of 2026. The divestiture of its gastroenterology business sharpens focus on higher-growth, higher-margin segments, namely AirSeal, Buffalo Filter and BioBrace. These platforms offer durable tailwinds: AirSeal benefits from rising robotic and laparoscopic procedure volumes and a large installed base, while Buffalo Filter is supported by increasing smoke-evacuation legislation and international adoption. BioBrace continues to gain traction as a differentiated orthopedic solution, with expanding clinical validation and surgeon adoption driving sustained growth.

Operationally, improving supply chain reliability is enabling the orthopedic segment to return to consistent mid-single-digit growth, with further acceleration expected as capacity expands. Additionally, raised organic growth guidance (5–6.5%) reflects improving business momentum and stronger execution.

However, challenges remain. The exit of GI creates a near-term revenue and earnings headwind, while OEM smoke products continue to weigh on general surgery performance. Inflationary pressures on input costs and higher interest expense from debt refinancing could also constrain margins. Despite these factors, CONMED’s focused portfolio and strengthening execution position it for steady growth in 2026.

CONMED’s Zacks Rank & Stocks to ConsiderCNMD currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Phibro Animal Health (PAHC - Free Report) andCardinal Health (CAH - Free Report) . While Globus Medical sports a Zacks Rank #1 (Strong Buy), Phibro Animal Health and Cardinal Health carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Globus Medical shares have gained 4% in the year-to-date period. Estimates for the company’s first-quarter 2026 EPS have increased 1 cent to 90 cents in the past 30 days. GMED’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 18.79%. In the last reported quarter, it posted an earnings surprise of 20.75%.

Estimates for Phibro Animal Health’s third-quarter fiscal 2026 EPS have remained constant at 72 cents in the past 30 days. Shares of the company have risen 45.3% in the year-to-date period against the industry’s 18.8% decline. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 20.15%. In the last reported quarter, it delivered an earnings surprise of 26.09%.

Cardinal Health shares have remained flat in the year-to-date period. Estimates for the company’s third-quarter 2026 EPS have decreased 1 cent to $2.80 in the past 30 days. CAH’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 9.30%. In the last reported quarter, it posted an earnings surprise of 10.04%.

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors (“Board”), effective July 1, 2026. Ms. Martin will serve as a member of the Audit Committee and the Strategy Committee, and Mr. Mirviss will serve as a member of the Compensation Committee and the Corporate Governance and Nominating Committee. In connection with these appointments, CONMED is increasing the size of its Board to include a total of nine directors.

“My fellow directors and I are delighted to welcome Celine Martin and Jeff Mirviss to the Board, both highly accomplished leaders with extensive experience developed at two of the largest companies in the healthcare industry,” said LaVerne Council, Chair of CONMED’s Board of Directors. “Celine joins our Board following a 30-year career at Johnson & Johnson, with deep global leadership experience in MedTech and a track record of driving innovation and growth. Likewise, Jeff possesses nearly 30 years of experience at Boston Scientific, where he led complex, global medical device businesses with operational and commercial excellence. Their insight and expertise will be invaluable to the Board as we advance CONMED’s long‑term strategy.”

“Celine and Jeff are outstanding additions to the Board,” said Patrick Beyer, President and Chief Executive Officer of CONMED. “Celine’s global strategic leadership and experience scaling high growth medical technology businesses, combined with Jeff’s expertise in portfolio leadership and execution across large, global organizations, will strengthen our governance and support our continued focus on delivering long‑term value for patients, customers, and shareholders.”

Over three decades at Johnson & Johnson, both in the U.S. and internationally, Ms. Martin played a vital role in advancing the ambition of J&J MedTech, developing new categories and advancing standard of care for atrial fibrillation, stroke, and minimally invasive surgery. Most recently, she served as Company Group Chairman leading the Cardiovascular & Specialty Solutions (“CSS”) Group from 2022 to 2025. As a member of the J&J MedTech leadership team, she ran a diverse portfolio of high growth businesses including Electrophysiology, Neurovascular Intervention, Ear Nose and Throat, and Breast Aesthetics. Before that, Ms. Martin led the Ethicon Endo Surgery business where she was instrumental in establishing the Robotic and Digital Surgery portfolio foundations. Ms. Martin holds an MBA from Wake Forest University and a graduate degree in marketing from Normandy Business School. Ms. Martin also serves on the Board of Directors at H.B. Fuller.

Mr. Mirviss brings more than 35 years of healthcare industry leadership experience. Most recently, he served as Executive Vice President and Global President of Peripheral Interventions at Boston Scientific from 2020 to 2025, where he led a multi-billion dollar global business focused on therapies for vascular disease and cancer. In this role, he also had leadership responsibility for the Company’s Latin America and Canada regions, as well as its Government Affairs function. Previously, Mr. Mirviss served as Senior Vice President and Global President of Peripheral Interventions from 2013 to 2020, and as Global President of Peripheral Interventions from 2011 to 2013. Prior to these roles, Mr. Mirviss held positions of increasing responsibility at Boston Scientific, including Group Vice President of Global Marketing for the Company’s Cardiology, Rhythm and Vascular businesses. Mr. Mirviss holds a B.I.S. in Marketing from the University of Minnesota and an MBA from the University of St. Thomas.

About CONMED Corporation

CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, and thoracic surgery. For more information, visit www.conmed.com.

Forward-Looking Statements

This press release may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2025, listed under the heading Forward-Looking Statements in the Company’s most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.

Key Takeaways Cardinal Health's Other Growth Businesses revenues rose 34% to $1.7 billion in fiscal Q3.CAH saw NPHS growth fueled by theranostics demand and At-Home Solutions expansion.CAH's OptiFreight revenues rose nearly 20%, boosting higher-margin growth exposure. Cardinal Health’s (CAH - Free Report) fiscal third-quarter results suggest that the company’s “Other Growth Businesses” are evolving from complementary assets into a meaningful profit engine, underscoring management’s strategy to diversify beyond its traditionally low-margin pharmaceutical distribution business.

In the third quarter of fiscal 2026, revenues from the segment surged 34% to $1.7 billion, while segment profit climbed at an even faster rate of 52%, highlighting the increasing earnings leverage of these higher-margin operations.

The momentum was broad-based, with strength coming from Nuclear and Precision Health Solutions (NPHS), At-Home Solutions and OptiFreight Logistics. NPHS continued to benefit from rapid adoption of theranostics, where revenues gained more than 30%, supported by Cardinal Health’s investments in isotope production capabilities and rising demand for targeted cancer therapies. Management emphasized growing engagement with pharmaceutical innovators, which includes the Actinium-225 platform that is already supporting more than 15 clinical trials globally.

At-Home Solutions is benefiting from the secular shift of healthcare services toward home-based care. Demand remained strong, aided by the successful integration of the Advanced Diabetes Supply (ADS) acquisition. Cardinal Health has now onboarded nearly 500,000 new patients and about 1,000 employees. The company is also migrating ADS volumes into its distribution centers, creating scale efficiencies and a stronger chronic-care platform. The business is also generating synergies with pharma through its ContinuCare Pathway program, which now serves 165,000 patients.

OptiFreight Logistics added another layer of growth, with revenues increasing nearly 20%, reflecting rising demand for cost-efficient healthcare logistics solutions. Together, these businesses are not only diversifying Cardinal Health’s revenue mix but also expanding exposure to faster-growing, higher-margin healthcare niches — potentially making them an increasingly important driver of long-term profitability.

Peer UpdateAlign Technology’s (ALGN - Free Report) future growth appears increasingly tied to deeper penetration of digital orthodontics and improved operating leverage. In the first quarter of 2026, the company reported record clear aligner shipments of 686,000 cases, supported by double-digit growth in international markets, especially APAC, EMEA and Latin America, while North America stabilized.

Future demand drivers for ALGN include expanding adoption among teens and children through products such as Invisalign First and Palatal Expander. Apart from product adoption, growing DSO partnerships, and financing initiatives are improving affordability and case conversion. Align Technology’s profitability is likely to be driven by AI-enabled treatment planning, lower refinement rates, operational efficiencies and higher-margin product configurations requiring fewer aligners, supporting sustained margin expansion.

CONMED’s (CNMD - Free Report) long-term growth and profitability outlook is likely to be driven by its focused portfolio strategy and higher-margin surgical platforms. Following the strategic divestiture of its gastroenterology business, management is concentrating resources on AirSeal, Buffalo Filter and BioBrace, which target attractive growth categories in the healthcare segment.

AirSeal should benefit from increasing robotic and laparoscopic surgeries, where penetration is still low. The U.S. laparoscopic procedures exceed 3 million annually, representing significant growth opportunity. Buffalo Filter has a favorable tailwind from expanding smoke-free operating room legislation, while BioBrace adoption continues to strengthen as surgeons embrace biologic soft-tissue repair solutions. Improving supply-chain reliability and a richer product mix should also support margin expansion and profit recovery.

CAH’s Price Performance, Valuation and EstimatesShares of CAH have lost 2.4% so far this year compared with the industry’s 8.2% decline.

Image Source: Zacks Investment Research

From a valuation standpoint, Cardinal Health trades at a forward price-to-earnings ratio of 16.98, above the industry average. It is also higher than its five-year median of 13.72. CAH carries a Value Score of A.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for Cardinal Health’s fiscal 2026 earnings implies a 30.1% rise from the year-ago period’s level, followed by 11.4% expected growth in fiscal 2027.

Image Source: Zacks Investment Research

The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Key Takeaways CONMED exited its GI portfolio to focus on higher-growth platforms with stronger margin potential.AirSeal's installed base tops 10,000 systems, with significant room for laparoscopic adoption.BioBrace gains traction in soft tissue repair, backed by growing clinical evidence and studies. CONMED Corporation (CNMD - Free Report) is well-positioned for growth on the back of rising adoption of its high-margin, differentiated platforms like AirSeal, Buffalo Filter and BioBrace. The company’s long-term prospects seem good as robotic procedure volume rises, coupled with the expanding penetration of Ambulatory Surgery Centers. Moreover, improving supply-chain bottlenecks should drive top- and bottom-line growth.

CONMED is facing tariff headwinds that are unfavorably impacting its earnings per share (EPS) and revenue expansion. Higher operating expense investments remain a concern.

Shares of this Zacks Rank #3 (Hold) company have lost 12.1% in the year-to-date period, underperforming the industry’s 9.2% decline and the S&P 500 Index’s 11.1% return.

Image Source: Zacks Investment Research

CONMED, a renowned global medical products manufacturer specializing in surgical instruments and devices, has a market capitalization of $1.07 billion. The company projects 5.1% earnings growth over the next five years.

The company’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 5.38%.

Factors Favoring CNMD StockStrategic Portfolio Simplification Should Improve Growth and Margin Quality: CONMED’s decision to fully exit its gastroenterology (GI) product portfolio represents a significant strategic shift toward higher-growth and higher-margin businesses. Management emphasized that the divestiture allows the company to redirect capital, commercial resources and management attention toward AirSeal, Buffalo Filter and BioBrace — three platforms with stronger competitive positioning and better long-term economics. While the GI business historically contributed to revenue generation, it carried lower strategic relevance and diluted growth rates. By concentrating investments on minimally invasive surgery, smoke evacuation and orthopedic soft tissue repair, CONMED is creating a more focused portfolio that should support faster organic growth, improved margin expansion and a clearer investment narrative over the next several years.

AirSeal Continues to Benefit From Multiple Structural Growth Drivers: AirSeal remains one of CONMED’s most important growth assets, supported by both robotic surgery expansion and underpenetrated laparoscopic procedures. The company now has an installed base exceeding 10,000 systems globally, providing recurring disposable revenues and strong surgeon familiarity. Beyond robotics, management highlighted that AirSeal is currently utilized in only 6-7% of the more than three million laparoscopic procedures performed annually in the United States, suggesting a substantial runway for adoption. CONMED placed more than 50% additional AirSeal units into the market compared with the prior-year quarter, which should support future disposable utilization. This combination of installed-base growth and low market penetration creates an attractive long-term growth profile.

BioBrace Emerging as a Differentiated Orthopedic Growth Platform: BioBrace continues to gain traction as a next-generation soft tissue repair technology and is increasingly becoming a cornerstone of CONMED’s orthopedic strategy. The implant uniquely combines structural reinforcement with biologic healing support, differentiating it from competing repair solutions. Management noted that surgeons are expanding the use of BioBrace across both primary repairs and more complex procedures, with more than 30 published studies strengthening clinical confidence. Additionally, the ongoing 268-patient randomized controlled trial could provide a powerful clinical catalyst. The trial is expected to complete enrollment in 2026. As orthopedic surgeons increasingly prioritize biologic augmentation and durability of repair outcomes, BioBrace appears well-positioned to capture share within a large and growing sports medicine market.

Supply Chain Recovery Creating Opportunity for Market Share Recapture: After several years of operational challenges, CONMED appears to be making meaningful progress in restoring supply chain reliability. Management stated that improvements achieved in late 2025 have been sustained through the first quarter of 2026, enabling orthopedic sales teams to become more proactive with customers rather than focusing primarily on product availability issues. Orthopedics delivered mid-single-digit growth for the third consecutive quarter, supported by improved service levels and stronger execution. Management believes customer relationships remained intact during supply disruptions, creating an opportunity to gradually regain lost business as contracts renew. A more reliable supply chain should not only support revenue growth but also improve operational leverage and customer confidence over time.

Downsides of CNMD StockRising Debt Costs Could Become a Meaningful Earnings Headwind: CONMED faces increasing financing costs as it refinances upcoming debt obligations. Management indicated that replacing expected convertible financing with traditional bank debt will increase interest expense and create at least a 10-cent EPS headwind in 2026, with potential implications extending into 2027. Long-term debt stood at approximately $860 million, while leverage remains around 3.1x EBITDA. Although management emphasized strong banking relationships and liquidity access, higher borrowing costs reduce financial flexibility and may limit future capital deployment options. In an environment where medtech valuations remain depressed and interest rates elevated, refinancing risk could continue to weigh on earnings growth and shareholder returns.

Smoke Evacuation Growth Still Being Offset by Weak OEM Performance: Buffalo Filter remains a compelling long-term opportunity, particularly as more states adopt smoke-free operating room legislation. However, near-term growth continues to be constrained by weakness in the OEM smoke evacuation business, which management described as a “meaningful headwind” during the first quarter. The OEM portion remains volatile and lumpy, creating quarterly revenue fluctuations that can mask the stronger performance of the direct smoke business. While management expects direct smoke evacuation to increasingly dominate the revenue mix over time, the transition period could create uneven growth patterns. Investors may therefore continue to see variability in reported performance despite favorable long-term legislative and clinical adoption trends.

Inflationary and Cost Pressures Could Limit Margin Expansion: Management acknowledged ongoing cost inflation across several key inputs, including oil-based materials, precious metals and medical device components. Although CONMED currently believes these pressures are incorporated into guidance and manageable through supplier negotiations and pricing actions, the company remains vulnerable to broader macroeconomic and geopolitical developments. Gross margin improved 100 basis points in the first quarter, aided by a favorable product mix, but sustaining that improvement may become increasingly difficult if commodity inflation accelerates or supply chain costs rise further. Given the company’s ongoing investment cycle and refinancing-related interest expense pressures, any inability to offset cost inflation could constrain future margin expansion and earnings growth.

Estimate TrendCONMED is witnessing a stable estimate revision trend for 2026. In the past 60 days, the Zacks Consensus Estimate for earnings has improved 2 cents to $4.38 per share.

The Zacks Consensus Estimate for second-quarter fiscal 2026 revenues and EPS is pegged at $337.2 million and $1.10, suggesting 1.5% and 4.4% declines, respectively, from the year-ago reported numbers.

Stocks to ConsiderSome better-ranked stocks from the broader medical space are Pacific Biosciences of California (PACB - Free Report) , Globus Medical (GMED - Free Report) and Biodesix (BDSX - Free Report) .

Globus Medical, sporting a Zacks Rank #1 (Strong Buy) at present, reported first-quarter 2026 adjusted EPS of $1.12, which outpaced the Zacks Consensus Estimate by 21.7%. Revenues of $760 million surpassed the Zacks Consensus Estimate by 4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% appreciation. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 26.26%.

Pacific Biosciences of California, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted loss per share of 12 cents, which surpassed the Zacks Consensus Estimate by 29.4%. Revenues of $37 million missed the Zacks Consensus Estimate by 9.3%.

PACB’s earnings are estimated to improve at a rate of 22.6% compared with the industry’s 13.3% growth in 2026. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 29.76%.

Biodesix, currently carrying a Zacks Rank of 2, reported a first-quarter 2026 adjusted loss per share of 81 cents, which beat the Zacks Consensus Estimate by 35.71%. Revenues of $26 million beat the Zacks Consensus Estimate by 12.3%.

BDSX has an estimated earnings growth rate of 36% for 2026 compared with the industry’s 12.5% return. The company beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 25.56%.